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Mohammad W. Aref 
BONE PERFUSION ALTERATIONS IN CHRONIC KIDNEY DISEASE  
Patients with chronic kidney disease (CKD) are at an alarming risk of 
fracture and cardiovascular disease-associated mortality. There is a critical need 
to better understand the underlying mechanism driving altered cardiovascular 
and skeletal homeostasis, as well as any connection between the two. CKD has 
been shown to have negative effects on many vascular properties including end-
organ perfusion. Surprisingly, exploration of skeletal perfusion and vasculature 
has not been undertaken in CKD. Alterations in bone perfusion are linked to 
dysregulation of bone remodeling and mass in multiple conditions. An 
understanding of the detrimental impact of CKD on bone perfusion is a crucial 
step in understanding bone disease in these patients. The goal of this series of 
studies was to test the global hypothesis that skeletal perfusion is altered in CKD 
and that alterations can be modulated through treatments that affect metabolic 
dysfunction. These studies utilized a rat model of CKD to conduct metabolic 
assessments, bone perfusion measurements, bone imaging studies, and isolated 
vessel reactivity experiments. Our results showed that animals with CKD had 
higher levels of parathyroid hormone (PTH), leading to substantial bone 
resorption. Bone perfusion measurements showed CKD-induced elevations in 
cortical bone perfusion with levels progressing alongside CKD severity. 
Conversely we show that marrow perfusion was lower in advanced CKD. PTH 
suppression therapy in animals with CKD resulted in the normalization of cortical 
bone perfusion and cortical bone mass, but did not normalize marrow bone 
v 
perfusion. These results show a clear association between bone deterioration 
and altered bone perfusion in CKD. While the relationship of altered bone 
perfusion and bone deterioration in CKD necessitates further work, these results 
indicate that determining the mechanisms of bone perfusion alterations and 
whether they are drivers, propagators, or consequences of skeletal deterioration 
in CKD could help untangle a key player in CKD-induced bone alterations. 
 
Matthew R. Allen, Ph.D., Chair 
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CHAPTER 1 
INTRODUCTION 
Patients with chronic kidney disease are at an alarming risk of 
cardiovascular disease and fracture-associated mortality. One in ten Americans 
suffers from chronic kidney disease (CKD) [1]. CKD results in a sequelae of 
physiological changes, including a triad of abnormal biochemistries, bone 
remodeling changes and vascular calcification, that culminate in increased 
morbidity and mortality. In CKD patients, the risk of cardiovascular disease is 
increased 2-3-fold and the risk of fracture 17-fold compared to the normal 
population with progressive rise in risk as kidney function deteriorates. More 
striking, cardiovascular disease accounts for nearly 60% of deaths in those with 
CKD (compared to 28% in the normal population); similarly over 60% of CKD 
patients that sustain a hip fracture die within a year (compared to 20% in the 
normal population) [2]. These striking statistics emphasize the critical need to 
better understand the underlying mechanism driving altered cardiovascular and 
skeletal homeostasis, as well as any connection between the two. 
The pathogenesis of chronic kidney disease—mineral and bone disorder 
(CKD-MBD) is driven by complex alterations in mineral metabolism. Disturbances 
in bone and mineral metabolism are a hallmark of CKD [3], [4]. Along with 
hyperphosphatemia, secondary hyperparathyroidism, and vascular calcification, 
patients exhibit alarming increases in the risk of cardiovascular disease and 
skeletal fractures [2,5-11,14-23]. Given the complexities of normal mineral 
metabolism, CKD-MBD encapsulates the compensatory mechanisms (and their 
2 
failure) that preserve calcium and phosphate homeostasis in the face of declining 
kidney function [12] (Figure 1-1). These physiological and pathological 
adaptations play a significant role in fracture risk and cardiovascular mortality 
[13-16].  
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Figure 1-1. Changes to mineral metabolism in CKD.   
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As kidney function begins to decline, there is an increased demand on the 
remaining nephrons to maintain mineral homeostasis and normal excretory 
functions[17,18]. Changes in phosphate excretion drive the metabolic 
derangements that characterize CKD-MBD. In response to increased phosphate 
load in the circulation, osteocytes increase secretion of FGF23, which acts on 
tubular epithelial cells in the kidney to decrease phosphate reabsorption. 
Elevated levels of FGF23 have been linked to ventricular hypertrophy and 
cardiovascular mortality [19-37]. In concert with elevated FGF23, parathyroid 
hormone (PTH) levels also increase to compensate for the rises in serum 
phosphate (though simultaneous declines in vitamin D synthesis occur in an 
attempt to temper PTH rises). While recent evidence indicates that FGF23 
normally suppresses PTH activity [38,39], secondary hyperparathyroidism 
ensues nonetheless, presumably due to the decreased expression of Klotho 
resulting in impaired FGF23 function. Initially, these responses effectively 
maintain normal serum phosphate levels. Eventually though, this process fails, 
and serum phosphate levels begin to increase despite continued elevations in 
PTH and FGF23. Rises in PTH levels lead to enormous increases in osteoclast 
differentiation and activity, which ultimately leads to the bone deterioration often 
present in CKD-MBD. While these pathways are beginning to be elucidated, the 
metabolic complexity of CKD has led to great challenges in understanding and 
treating skeletal and cardiovascular manifestations, resulting in an inability to 
minimize fracture risk and mortality in this population.  
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Metabolic changes in CKD lead to significant changes in structure/function 
of cardiovascular and skeletal tissue. The connection between kidney disease 
and cardiovascular abnormalities was first made in the 19th century [15]. Since 
then, numerous studies have illustrated the connection between decreased 
kidney function in CKD [40-46] and disorders of mineral metabolism [61][62-
64][65-67]  with a wide array of cardiovascular diseases. In a rat model of CKD, 
chronic elevations of PTH have been implicated in lowering cardiac contractility 
and adversely affecting energy utilization in myocardial tissue [54], increasing 
myocardial calcium deposition, hypertrophy and fibrosis and vascular calcification 
[55,56], increasing mitral annular calcification [57], impairing arterial vasodilation 
[58], and causing wall-thickening of intramyocardial arterioles independent of 
blood pressure [59].   
 Patients with chronic kidney disease have more than double the risk of 
having a fracture compared to the general population [6,7]. Of even greater 
concern, mortality rates in CKD patients with hip fractures more than double that 
of non-CKD patients with hip fractures [8]. The presence of secondary 
hyperparathyroidism causes changes in bone metabolism that lead to the 
preferential breakdown of cortical bone. Specifically, chronic elevations in PTH 
can lead to subperiosteal and intracortical erosion, resulting in drastic increases 
in cortical porosity [60]. The impact on cancellous bone is more variable. In cases 
of mild hyperparathyroidism, cancellous bone is usually unchanged or even 
increased [61]. Other imaging studies indicate that hyperparathyroidism can also 
detrimentally impact trabecular bone in CKD [62]. Nevertheless, cortical bone is 
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most prominently impacted, which may explain why BMD estimates in the distal 
radius and tibia (and not the hip or spine) are the strongest predictors of fracture 
in these patients. Specifically, CKD patients with a history of fracture have lower 
volumetric BMD and thinner cortices than those without fractures [60].  
Animal models present an opportunity to explore the relationship between 
cardiovascular alterations and skeletal deterioration in CKD. Because of the 
widespread impact of CKD on human health, numerous animal models have 
been developed to address the systemic repercussions of kidney disease. The 
most common approach is to induce end stage renal disease by surgical subtotal 
nephrectomy (with numerous variations), electrocautery, or the administration of 
adenine. These models represent an acute injury that leads to chronic renal 
failure. Given that the vast majority of patients with CKD have either hypertensive 
nephropathy or diabetic nephropathy [63], sudden trauma does not accurately 
represent the progression of disease that occurs in the majority of human CKD 
cases. While adenine does provide a slower disease progression (three to four 
weeks), animals exhibit severe weight loss not seen in other models [64]. The 
consequences of this weight loss on pertinent disease parameters are unclear. 
Despite the drawbacks of acute onset, these models still have important potential 
for examining the impact of CKD on mature cardiovascular and skeletal tissue.  
The effects of subtotal nephrectomy in rodents on the cardiovascular 
system resemble those seen in human CKD [65], although severe hypertension 
is not common in this model. Pathologies documented in the subtotal 
nephrectomy model include left ventricular hypertrophy [66] along with increases 
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in myocyte cross-sectional area [67], interstitial fibrosis [67], and increases in 
capillary density [68]. With regards to skeletal tissue, most of these data derive 
from experiments in which CKD is induced in skeletally immature animals with 
actively growing bones [69] [70]. Not only do these animals exhibit rapid bone 
modeling not present in adult rodents, but there also is no way to distinguish the 
direct impact of kidney disease on bone from its impact on altered skeletal 
development.  
Alternative models use genetic manipulation to induce kidney failure, 
primarily in the form of polycystic kidney disease [71]. For example, the jck 
mouse has a primary ciliary defect that leads to cystic kidney disease by four 
weeks of age. Similarly, pcy mice exhibit ciliary disease leading to cysts by three 
weeks. The greatest challenge with most genetic models is the rapid onset of 
disease during early growth and development. As above, this makes it 
exceedingly difficult to determine if skeletal manifestations are a direct result of 
the disease or rather an indirect byproduct of disturbed skeletal development. 
While these are important models for pediatric CKD, their application to end 
stage disease in adults is limited. 
The model utilized in the current study (the Cy/+ rat) avoids many of these 
drawbacks.  The Cy/+ rat, developed here at IUSM by the late Dr. Vince Gattone, 
is characterized by autosomal dominant polycystic kidney disease [72]. Based 
upon its gradual development of mineral disturbances and similar response to 
current therapies, our laboratory has demonstrated that it accurately 
recapitulates several aspects of human CKD [72,73]. Blood urea nitrogen (BUN) 
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and creatinine are elevated by 20 weeks while progressive hyperphospatemia, 
hyperparathyroidism, and skeletal abnormalities, are all present by 30 weeks. By 
35 weeks of age there are dramatic manifestations of cardiac and vascular 
calcification as well as severe cortical porosity and compromised mechanical 
properties (Figure 1-2). The apparent and clinically relevant dysfunction in 
cortical bone observed in this model provides an opportunity to study the 
possibility of dysfunctions in skeletal blood flow in CKD. Although both males and 
females display disease progression, males do so more quickly and thus have 
been the focus of most previous experiments [73,74]. Because of this 
preponderance of data, males will be utilized here with the long-term goal of 
assessing sex-differences.  
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Figure 1-2.  Cardiac calcification and cortical porosity in the Cy/+ model. The 
Cy/+ model develops cardiac calcifications (upper panels show normal (on left) 
and two Cy/+ animals at 35 weeks via CT) and severe skeletal destruction (lower 
panels (left is normal; right is CT image of a Cy/+ tibia at 35 weeks). 
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Overall, the Cy/+ rat provides an advantage as it allows for the analysis of 
skeletal defects in a model that exhibits progressive development of both CKD 
mineral metabolism and skeletal abnormalities [64]. Normal bone is allowed to 
develop prior to the onset of disease, mimicking the gradual development of CKD 
in human adults.  
Skeletal perfusion is essential to bone health. Bone blood flow plays a 
crucial role in bone growth [75], fracture repair [76-78], and bone homeostasis 
[79,80]. The vascularity of bone dictates its degree of cellularity, remodeling and 
repair [81]. Disturbances to bone blood flow have been shown to have 
deleterious effects on bone health and function [79,82-85].  Conditions that alter 
bone remodeling (diabetes, disuse, aging, estrogen withdrawal, anabolic drug 
treatment) have all been associated to changes in bone blood flow and 
properties of the principal nutrient artery (PNA), the main resistance vessel to 
each long bone [82,83,86-91]. Moreover, disturbances to bone vasculature, due 
to any of a number of potential causes, result in alterations in tissue perfusion 
and local hypoxia [92]. Reduced bone perfusion has been associated with bone 
loss [93]  in a number of conditions, including aging, inflammation, infection, 
fractures, unloading, tumors, diabetes, smoking, and glucocorticoids (Table 1-1). 
Additionally, impairments to bone blood supply have been shown to reduce 
growth and repair [94]. The effects of local hypoxia on bone cell function dictate 
the effects of disturbances to bone vasculature on bone health. Hypoxia has 
been shown to stimulate bone resorption by accelerating the formation of 
osteoclasts and ultimately increasing osteoclast number [95]. The formation of 
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functional osteoclasts occurs though the differentiation of mononuclear 
precursors following extravasation into oxygen-deficient bone microenvironments 
[93,96,97]. Hypoxia has also been shown to inhibit osteogenesis due to 
decreased differentiation of osteoblasts, along with inhibition of cell proliferation, 
collagen production, and alkaline phosphatase expression [93,98]. 
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Table 1-1. Summary of bone vascular dysfunction in diseases, conditions and 
treatments 
Condition 
Effect of disease on bone vascular 
properties 
Skeletal Disease  
Post-menopausal 
Osteoporosis 
• Decrease in blood vessel volume - Reduced 
medullary canal vascularity, including 
capillary rarefaction and decrease expression 
of angiogenesis-related HIF-1a, HIF-2a, and 
VEGF proteins in aging humans and 
ovariectomized mice  [99] 
Osteonecrosis • Reduced bone blood supply that results in 
increased osteoclast differentiation  [100] 
Avascular necrosis of 
the femoral head 
• Decreased neovascularization caused by low 
number of endothelial progenitor cells 
(EPCs), their diminished capacity to migrate 
and increased senescence in humans [101] 
• Blood flow interruption caused by damage of 
the endothelial cell membrane [101] 
Osteopetrosis • Blood perfusion to the bone affected by the 
obliteration of medullary spaces combined 
with granulocytopenia, anemia and ischemia, 
commonly lead to necrosis and osteomyelitis 
[102] 
 
Vascular Disease  
Atherosclerosis • Oxidized lipids produced during 
atherosclerotic plaque formation within bone 
blood vessels negatively affect bone mass by 
increasing anti-osteoblastic inflammatory 
cytokines and decreasing pro-
osteoblastogenic Wnt ligands in ApoE-
knockout, high-fat-diet-fed mice [103] 
Systemic Disease  
Diabetes Mellitus • Diabetes-induced microangiopathy causes 
vasoconstriction and impairs blood flow with 
long bones of rats [84] 
• Decreased blood vessel supply - decreased 
marrow vascularity [104] 
• Advanced glycation end products (AGEs), 
produced in diabetes may also disrupt bone 
vasculature [105] 
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Chronic Kidney 
Disease (Secondary 
Hyperparathyroidism) 
• Increased cortical bone perfusion [106] 
• Decreased marrow perfusion [106] 
• Decreased marrow VEGF [107] 
Sickle Cell Anemia 
(and other anemias) 
• Decreased oxygen delivery to bone [108] 
Chronic Obstructive 
Pulmonary Diseases 
• Decreased oxygen delivery to bone [109] 
Therapy   
Teraperatide 
(Anabolic Therapy) 
• Increased vascular volume and increased 
perfusion [110] 
• Increased VEGF and increased vasodilatory 
principal nutrient artery of the femur [90] 
Bisphosphonate • Treatment with pamidronate or zoledronate 
has been reported to reduce vascular 
endothelial growth factor (VEGF) levels [111] 
and bone blood flow in rats [112] 
 
 
Skeletal Tumors • Increased vascularity [113] 
Aging Decreased perfusion due to vascular 
rarefaction, reduced angiogenesis, diminished 
vasodilator capacity, vascular calcification, 
arteriosclerosis, and atherosclerosis in humans 
[86,87,114] 
Substance Abuse  
Smoking • Possible link between vasoconstriction due to 
nicotine and epidemiological evidence linking 
smoking to osteoporosis [115] 
Alcohol • Possible link between vascular disease 
(increased BP and triglycerides) and 
osteopenia leading to skeletal fractures 
[116,117] 
Fracture  • Short term vasodilation of existing/remaining 
intact vasculature following injury [118] 
• Angiogenesis around and within fracture 
callus [76-78] 
Unloading  • Decreased blood flow and increased vascular 
resistance [83] 
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Preclinical assessment of bone perfusion allows the exploration of 
relationships between bone health/disease and bone perfusion. Radioactive 
microspheres were long considered the experimental gold standard for the 
determination of skeletal perfusion [80] due to their accuracy and ease of 
analysis [119]. Upon injection into the animal, microspheres lodge in tissue 
capillaries in direct proportion to the fraction of cardiac output perfusing the tissue  
[80]. Tissue analysis is relatively straightforward, even for mineralized tissue, in 
that once tissues of interest are harvested, blood flow is estimated via a gamma 
spectrometer with minimal tissue processing [83,85,120,121]. Various limitations 
of radioactive microspheres, including cost, health risks, and the necessity for 
precautions with use and disposal [122], have resulted in exploration of 
alternative methods. Alternative methods of preclinical perfusion measurements 
are laser doppler flowmetry and positive emission tomography (PET). 
Microsphere injection is a static measurement, while Laser Doppler and PET are 
continuous measurements. Laser Doppler does not provide anatomical data and 
is not likely to be useful as a measure of blood flow because the size of the 
vessels could be different and would not be measurable. Different size vessels 
would affect flow and thus potentially unknowingly confound the measure.  
Fluorescent microspheres, which work on the same principal as 
radioactive spheres in that they become entrapped within capillaries, have been 
shown to allow measurement of organ perfusion as effectively as radioactive 
microspheres [122]. Analysis of fluorescent microspheres requires degradation 
and filtration of the tissues of interest before the samples can be analyzed and 
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has been effectively used in numerous soft tissue across multiple species 
[119,122-125]. Processing of skeletal tissue presents more challenges for 
fluorescent microspheres compared to soft tissue, perhaps helping to explain 
why the fluorescent microsphere method has only been performed in two 
models: mice [126] and rabbits [119]. The current series of studies will utilize 
fluorescent microspheres to measure bone perfusion in rats with CKD.  
The functional anatomy of long bone blood supply is crucial in 
understanding the potential role of bone perfusion in CKD bone disease. Long 
bones have four main arterial inputs: nutrient arteries that penetrate the 
diaphysis, periosteal arteries that are on the bone surface within the periosteum, 
metaphyseal arteries, and epiphyseal arteries [127]. Cortical bone in the 
diaphysis is perfused by arterial blood originating from 1) the main nutrient 
arteries as well as 2) smaller periosteal arteries [81] (Figure 1-3). The main 
blood supply of the marrow originates from the nutrient artery, which originates 
from large arteries of the extremities (i.e. femoral/tibial and brachial/radial 
arteries), penetrates the cortex and divides into ascending and descending 
branching running along the length of the bone within the medullary cavity [128]. 
The main nutrient artery running longitudinally through the medullary cavity will 
supply the medullary sinuses in the marrow along with cortical branches directed 
back toward the endosteum. The cortical branches of the nutrient artery pass 
through endosteal canals and supply arterial blood to fenestrated intracortical 
capillaries in the Haversian canal system. Intracortical capillaries anastomose 
with periosteal plexuses formed by arteries from neighboring connective tissue. 
16 
Thus, perfusion of cortical bone in long bones is centrifugal, originating from the 
nutrient artery in the marrow cavity and anastomosing with periosteal plexuses in 
the periosteum [128] [81]. Perfusion of the bone can be compromised with either 
disrupted vascular supply or altered vascular network within the cortex and 
medullary cavity.  
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Figure 1-3: Diaphyseal bone perfusion.  
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Chronic kidney disease has negative effects on vascular reactivity and 
end-organ perfusion. In the setting of CKD, decreased cardiac output [129], 
vascular calcification [130], and endothelial dysfunction [131-133] could all 
contribute to altered end-organ perfusion. Hypoperfusion, in CKD patients, that 
causes ischemia has been illustrated in the myocardium [134], brain [135,136], 
and mesentery [137]. However, studies that elucidate the effect of individual 
cardiovascular pathologies on end-organ perfusion in CKD have yet to be 
performed. Moreover, CKD-induced elevations in uremic toxins including 
phosphate [138] and parathyroid hormone (PTH) [110] have long been 
associated with vascular dysfunction through endothelium-dependent, 
endothelium-independent and/or vascular remodeling mechanisms [139-142]. 
Extensive work in CKD has documented vascular changes to coronary vessels 
[143,144] and aorta [145,146]. Gastrointestinal resistance arteries, which control 
organ perfusion, have also been shown to be adversely affected in models of 
CKD [147-150]. Other work has illustrated structural remodeling of resistance 
arteries manifested as alterations in arteriolar wall thickness and lumen diameter 
[151,152]. Surprisingly, the effects of uremia, including elevations in PTH and 
phosphate, on skeletal perfusion and vasculature have not been studied. 
Parathyroid hormone (PTH) acts directly on vascular smooth muscle cells 
and modulates bone vasculature. Cardiomyocytes and vascular smooth muscle 
cells both have PTH receptors [153]. In cardiomyoctytes, PTH activates protein 
kinase C which increases hypertrophic growth that might contribute to left 
ventricular hypertrophy. In vascular smooth muscle cells, PTH increases cAMP 
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levels and inhibits L-type calcium channel, which results in vasorelaxation [153-
154]. Early studies illustrated the acute effects of intravenous injection of PTH on 
bone blood flow [154]. Bone blood flow to the tibia and femur was increased 30 
minutes after administration of intravenous PTH. This pointed toward a dilatory 
effect in bone vasculature that was confirmed more recently in a study that 
showed that PTH enhanced endothelium-dependent vasodilation of the femoral 
PNA via augmented nitric oxide production [90]. As is expected given the 
divergent effects of intermittent and continuous PTH on bone mass, the effect of 
PTH on bone vasculature is dependent on the time-course of PTH 
administration. In a recent study, intermittent PTH stimulated bone formation and 
prevented OVX-induced reduction in bone perfusion and bone vessel density, 
while continuous PTH resulted in a decrease in vessel size [110]. Another study 
showed that treatment with teriparatide resulted an increase in bone blood flow, 
evaluated for up to 18 months [155]. Although secondary hyperparathyroidism is 
prevalent in CKD and has been implicated as one of the factors that results in 
skeletal deterioration in CKD, the potential effects of PTH on skeletal blood flow 
and the consequential deterioration of skeletal health have not been studied in 
CKD. Chronic elevations in parathyroid hormone (PTH) may drive altered bone 
vascular properties in CKD. In a rat model of CKD, we and others have shown 
that sustained elevated PTH contributes to high bone remodeling which drives 
increases in cortical porosity and ultimately compromised bone mechanics 
[156,157]. Moreover, the role of PTH in modulating vasculature, including that of 
the bone, has been well-established in the literature [91,110,158,159]. Based on 
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this, and the above established scientific premise, the goal of the present series 
of studies is to test the hypothesis that chronic elevations in PTH drive 
maladaptive changes to the skeletal vasculature that contribute to the skeletal 
manifestations in CKD. 
 CKD is a systemic disease that is known to detrimentally alter both the 
vascular and skeletal systems, and potentially also the bone vascular system. 
Figure 1-4 illustrates the potential relationships between systemic disease, 
vascular disease, skeletal disease, and alterations to the bone vascular network. 
Understanding the underlying mechanisms of bone vascular alterations due to 
the sequelae of reduced kidney function, including mechanisms that overlap with 
cardiovascular and skeletal alterations, is crucial to developing novel ways to 
reduce mortality in CKD patients.  
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Figure 1-4: Bone vascular dysfunction and bone disease.  
1. Systemic diseases can affect bone health, structure, and function 
2. Systemic diseases can affect vascular health, structure, and function 
3. Vascular disease/dysfunction/disturbances can result in bone vascular 
disease/dysfunction/disturbances  
4. Bone vascular disease/dysfunction/disturbances can cause/play a role in 
bone disease  
5. Bone disease can cause bone vascular alterations (that can then play a 
role in bone disease - 4) 
6. Disturbances to bone vascular network can result in altered marrow health 
that can contribute to systemic pathophysiology 
7. Bone diseases can cause mineral disorders that can contribute to 
systemic pathophysiology  
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CHAPTER 2 
ASSESSMENT OF REGIONAL BONE TISSUE PERFUSION IN RATS USING 
FLOURESCENT MICROSPHERES 
Introduction 
Bone blood flow plays a crucial role in bone growth [75], fracture repair 
[76-78], and bone homeostasis [79,80]. Disturbances to bone blood flow have 
been shown to have deleterious effects on bone health and function [79,83-
85,87] yet there remain many unanswered questions about skeletal perfusion in 
health and disease, partially due to the complexity of measurement 
methodologies  [80].  
 Radioactive microspheres were long considered the experimental gold 
standard for the determination of skeletal perfusion [80] due to their accuracy and 
ease of analysis [119]. Upon injection into the animal, microspheres lodge in 
tissue capillaries in direct proportion to the fraction of cardiac output perfusing the 
tissue  [80]. Tissue analysis is relatively straightforward, even for mineralized 
tissue, in that once tissues of interest are harvested, blood flow is estimated via a 
gamma spectrometer with minimal tissue processing [83,85,120,121]. Various 
limitations of radioactive microspheres, including cost, health risks, and the 
necessity for precautions with use and disposal [122], have resulted in 
exploration of alternative methods.  
Fluorescent microspheres, which work on the same principal as 
radioactive spheres in that they become entrapped within capillaries, have been 
shown to allow measurement of organ perfusion as effectively as radioactive 
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microspheres [122]. Analysis of fluorescent microspheres requires degradation 
and filtration of the tissues of interest before the samples can be analyzed and 
has been effectively used in numerous soft tissue across multiple species 
[119,122-125]. Processing of skeletal tissue presents more challenges for 
fluorescent microspheres compared to soft tissue, perhaps helping to explain 
why fluorescent sphere data exists only for mice [126] and rabbits [119].  
In the present study, we sought to use fluorescent microspheres in rats to 
assess regional bone perfusion. The goal was to adapt a fluorescent 
microsphere protocol used in mice [126] to determine the variability of skeletal 
perfusion both within and among a set of normal rats, as well as to test various 
perturbations in experimental methodology. 
 
Methods 
Microsphere storage and fluorescence decay 
In order to determine characteristics of the microspheres, several 
perturbations in storage and analyses were carried out prior to animal 
experiments. The effect of different methods of storage on fluorescence 
quantification was examined by placing a known amount of microspheres 
(50,000 beads in 0.05mL) in either phosphate buffered saline (PBS) or ethanol 
(EtOH). Additional sets of microspheres were placed in PBS and frozen at -4C or 
-20C. Finally, the stability of fluorescence over time after being released from the 
microspheres was measured over 10 days. 
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Animals 
 Fifteen-week old male Sprague Dawley rats (n=10) were used for this 
study. All procedures were approved by the Indiana University School of 
Medicine Animal Care and Use Committee prior to initiating the study. 
 
Microsphere injection 
 Polystyrene, red fluorescent (580/605), 15 µm microspheres 
(FluoSpheres, ThermoFisher), were used for blood flow determination. 
Microsphere injection in half of the rats (n=5) was performed as previously 
described with minor adaptations for rats [126]. The process is summarized and 
illustrated in Figure 2-1. Briefly, under isoflurane anesthesia, the chest cavity 
was opened to allow visualization of the heart. A 2.5 mL solution of microspheres 
(containing one million spheres/mL) was injected in the apex of the left ventricle 
of the beating heart. The spheres were allowed to circulate for 60 seconds before 
the animal was euthanized and tissues collected. The number of microspheres 
injected was based, on a mg/kg basis, off of using 2x105 microspheres for a 43g 
mouse which works out to 4.65x106 spheres/kg; we rounded up to 5.0x106 
spheres/kg for ease [126]. A pilot study was done to verify that the number of 
spheres entrapped in bone vasculature using a 2.5 million sphere injection was 
within the generated standard curve used to estimate microsphere number. Due 
to the potential variability of cardiac function after opening the chest cavity, 
another five rats were administered a similar number of microspheres (2.5 
25 
million) via a tail vein catheter.  For these animals, microspheres were allowed to 
circulate for 5 minutes before the rats were euthanized and tissues collected.  
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Figure 2-1:  Graphical depiction of microsphere protocol including microsphere 
injection, tissue processing and fluorescence quantification. 
 
  
27 
Sample Processing 
 Femur and tibia samples were divided into proximal, middle (diaphysis), 
and distal segments as previously described [83].  Marrow was left intact in all 
bone specimens. Bone samples were placed in individual amber vials with 15mL 
of Cal-Ex Decalcifier solution. After 4 days, decalcified bone samples were 
placed in 5% ethanolic postassium hydroxide for degradation. Samples were 
vortexed every 24 hours to ensure complete degradation. After 96 hours of 
degradation, samples were filtered through polyamide mesh filters (5 µm pore 
size). 1mL of Cellosolve acetate (2-ethoxyethyl acetate, 98%, Sigma, cat. no. 
109967) was added to each of the filtered samples to break the microspheres 
open and expose the fluorescence.  
 
Fluorescence quantification 
 All fluorescence measurements were made using the SpectraMax i3x 
microplate reader (Molecular Devices, CA). Three 100µL aliquots from each 
sample were placed in a 96-well microplate for fluorescence quantification. Red 
fluorescence was measured using an excitation of 580nm and an emission of 
620nm. Standard curves of serial dilutions with known amounts of microspheres 
were generated on the day of analysis. Standard curves generated were used to 
approximate the number of spheres in a given sample. All data is presented as 
tissue fluorescence density (TFD) as AU/g and scaled by 106.   
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Statistical Analysis 
All analyses were performed using the Statistics Toolbox in MATLAB 
software. Paired student t-tests were utilized to compare right and left TFD 
measurements of the femora and tibiae. A priori a-levels were set at 0.05 to 
determine significance. Coefficients of variation (CV) were calculated within each 
bone segment (using data from both right and left limbs; n=10).  
 
Results 
Neither storage of intact microspheres in EtOH or freezing temperatures 
for 24 hours altered fluorescence of the spheres compared to recommended 
storage in PBS (Figure 2-2A). Furthermore, measurement of fluorescence 
showed no decay after 4 or 10 days relative to measures taken immediately after 
fluorescence release (Figure 2-2B).  
Tissue fluorescence density (TFD) data for the various regions of femora 
and tibia from animals administered microspheres through the left ventricle are 
presented in Table 2-1. Right and left total femoral TFD (2.77 ± 0.38 and 2.70 ± 
0.24, respectively) from animals with microspheres injected in the left ventricle 
were not significantly different (p=0.75). Right and left tibial TFD (1.11 ± 0.26 and 
1.08 ± 0.34, respectively) were also not different (p=0.59). The coefficient of 
variation (CV) of TFDs among the five animals was 10.95% and 26.06% for the 
femur and tibia, respectively. Partitioning of the tissue perfusion into three 
segments along the length of the bone showed the proximal femur received 
27.30 ± 4.04%, the distal femur 51.34 ± 7.97%, and the femoral diaphysis 21.36 
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± 6.68% of total femoral perfusion (Figure 2-3). The tibia partitioning showed 
proximal tibia received 68.77 ± 5.86%, the distal tibia 10.68 ± 4.18%, and the 
tibial diaphysis 20.55 ± 5.86% of total tibial perfusion. Bone segment masses are 
presented in Supplementary Table 1.  
Tail vein injection resulted in unacceptably low levels of tibia perfusion 
(TFD) in the tibia from 4 of the 5 animals (Table 2-2). Analyses of femora from 
these animals was not undertaken. 
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Figure 2-2: Microsphere standard curves displayed as bead quantity and 
fluorescence. (A) Effects of storage conditions. (B) Effects of time. 
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Figure 2-3: Tissue fluorescent density (TFD) of segmented femur (A,C) and tibia 
(B,D). RPF, Right proximal femur; LPF, Left proximal femur; RFD, Right femoral 
diaphysis; LFD, Left femoral diaphysis; RDF, Right distal femur; LDF, Left distal 
femur; RPT, Right proximal tibia; LPT, Left proximal tibia; RTD, Right tibial 
diaphysis; LTD, Left tibial diaphysis; RDT, Right distal tibia; LDT, Left distal tibia.. 
Data presented as means and standard deviations. 
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Discussion 
The importance of bone blood flow in skeletal health, and its role in 
disease has been established through several preclinical experiments. Although, 
the gold standard for bone blood flow measurement has been the injection of 
radioactive microspheres, fluorescent microspheres have been established as a 
safer and equally effective technique for non-skeletal tissues (such as lung, 
kidney, and brain). Measures of bone blood flow using fluorescent microspheres 
presents challenges due to the difficulty of imaging through mineralized tissue 
and the technical difficulty of current microsphere assays, especially in small 
animals. The current work extends the use of fluorescent microspheres, 
described in detail for mice [126], to assess bone perfusion in rats.  
 Although the use of fluorescent microspheres has been well detailed in 
mice [126], some protocol adaptations were needed to measure fluorescent 
microspheres in rat.  A larger absolute number of microspheres was used based 
on the recommendation of approximately 5 million spheres per kg of body weight 
used successfully in mice [126].  Due to larger volume of tissue in rat compared 
to mouse, larger volumes of ethanolic KOH were needed to degrade the tissue. 
Segments of bone were placed in 15mL of 10% ethanolic KOH (vs 8mL of 3% 
ethanolic KOH in mice).  Also due to the larger tissue volume, a larger vacuum 
filtration apparatus was necessary to filter the degraded samples. Degraded 
samples were filtered through 47mm polyamide filters (versus 25mm filters used 
in mice).  
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 Our results on tibia and femoral perfusion match closely with previous 
reports examining values across these two bones as well as regionally within 
each bone. The ratio of femoral to tibial perfusion reported in the current work 
matches the results of previous studies performed using microspheres in rats 
[160] [112] and dogs [161]. The percentage of tissue perfusion to the different 
segments of the femur and tibia reported in our work also match values using 
radioactive microspheres showing highest flow in distal femur and proximal tibia 
[162]. This congruence with previous work lends support to the viability of the 
fluorescent microsphere technique for assessing bone perfusion in rats. 
Many regional organ perfusion protocols using microspheres require 
technically challenging surgical techniques including catheter placement into the 
left ventricle to inject microspheres, and another catheter placement in the 
carotid artery or the tail artery to collect a reference blood sample. These 
techniques are further complicated when performed in rodents, given the smaller 
size of vessels. Because of potential variability in several steps of the sphere 
administration process, it is worthwhile to find an alternative way to assure 
adequate spheres are administered. The use of blood as a reference tissue has 
been used extensively, but other protocols have used organs as the reference 
tissue [126]. The advantage of using an organ as a reference tissue is it 
eliminates the need for catheter placement in vessels while the animal is alive. 
While this will work for interventions that are isolated (such as limb cooling used 
in the mouse protocol [126]), our end-goal of this work is to study skeletal 
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perfusion in the context of systemic disease which will likely affect blood flow 
systemically (and potentially differently across skeletal sites).  
 In the current study, microspheres were injection into the left ventricle after 
opening the chest cavity while the animal was under anesthesia as a terminal 
procedure. Variability in cardiac function before the animal is euthanized due to 
invasion of the chest cavity was not assessed in the present study and could 
account for variability among animals. In an attempt to reduce this variability, 
injections were performed in the tail vein for a subset of animals in order to allow 
the animal to maintain normal cardiac function to distribute the spheres 
systemically. Although it was assumed that spheres would be entrapped in the 
pulmonary capillaries, if enough microspheres passed through to the arterial 
system, bone perfusion could be measured while also preserving cardiac 
function. Our results clearly showed that microsphere entrapment in bone was 
insufficient for reliable measure and thus this is not a viable method of 
administration.   
In the present study, we have shown that the injection of fluorescent 
microspheres in the left ventricle of rats is an effective method for the estimation 
of bone perfusion. However, there are a number of limitations to this study. Due 
to the fact that we did not collect a blood sample during injection, we are unable 
to calculate an estimated flow rate to bone. Although a flow rate provides an 
easily interpretable value (mLs per minute per tissue weight), it is worth noting 
that collection of reference blood from the tail artery, as many do [163] [164], 
likely underestimates the concentration of spheres in organs since it is distal to a 
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majority of the arterial tree including highly vascularized tissue including the brain 
and kidneys. Another limitation to our study is the lack of hemodynamic stability 
during the microsphere injection procedure and microsphere circulation. The 
animals are anesthetized using isoflurane, which is known to affect organ 
perfusion [165] and cardiovascular dynamics [166]. Finally, without the use of 
assisted ventilation, this is a terminal procedure and does not allow for the serial 
injection of microspheres for the evaluation of longitudinal change in skeletal 
perfusion.  This could be overcome by administration of spheres via prolonged or 
repeated catheterization if longitudinal measures are of interest.  
Although the use of fluorescent microspheres is emerging as an accepted 
alternative to radioactive microspheres as a method for the measurement of 
blood flow, and some papers have used the technique to examine bone, there 
has yet to be a study to assess these techniques in rats. The current work fills 
this void by showing the viability of injection and analysis of fluorescent 
microspheres to assess regional bone tissue perfusion in rats. 
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Tables 
 
Table 2-1: Tissue fluorescence density in the femur and tibia following intra-
cardiac injection of microspheres 
 
 
 
Tissue fluorescence density (TFD) data presented as AU/g and scaled by 106. CV 
= coefficient of variation among right and left (combined together so n=10 
specimens per CV) bone segments across all five animals. 
  
Femur 
 Proximal Diaphysis Distal Total 
Animal Right Left Right Left Right Left Right Left 
1 2.01 2.17 1.08 1.27 5.02 5.57 2.73 2.80 
2 1.78 1.86 2.40 1.40 4.19 4.37 2.77 2.63 
3 2.30 2.87 1.64 1.72 4.15 3.75 2.84 2.90 
4 3.10 2.50 3.24 2.45 3.51 3.51 3.28 2.83 
5 1.73 1.61 1.84 1.78 3.13 3.60 2.22 2.31 
Mean  2.18 2.20 2.04 1.72 4.00 4.16 2.77 2.70 
Stdev 0.56 0.50 0.82 0.46 0.72 0.86 0.38 0.24 
CV 0.23 0.34 0.18 0.11 
Tibia 
 Proximal Diaphysis Distal Total 
Animal Right Left Right Left Right Left Right Left 
1 2.45 2.51 0.63 0.39 1.40 1.06 1.51 1.37 
2 2.25 2.49 0.49 0.59 0.57 0.81 1.13 1.44 
3 1.14 1.46 0.60 0.49 0.52 0.46 0.81 0.87 
4 2.04 1.14 0.55 0.23 0.52 0.26 1.12 0.63 
5 1.45 1.75 0.60 0.71 0.57 0.39 0.96 1.10 
Mean  1.87 1.87 0.57 0.48 0.72 0.60 1.11 1.08 
Stdev 0.55 0.61 0.06 0.19 0.38 0.33 0.26 0.34 
CV 0.29 0.26 0.52 0.26 
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Table 2-2: Tibia tissue fluorescence density following cardiac versus tail vein 
microsphere injection  
 
 
Animal Cardiac injection Animal Tail injection 
Right 
tibia 
Left 
tibia 
Right 
tibia 
Left 
tibia 
1 1.51 1.37 6 1.04 1.34 
2 1.13 1.44 7 0.04 0.02 
3 0.81 0.87 8 0.03 0.01 
4 1.12 0.63 9 0.02 0.01 
5 0.96 1.10 10 0.03 0.02 
Mean 1.11 1.08  0.23 0.28 
Stdev 0.26 0.34  0.45 0.59 
 
Tissue fluorescence density (TFD) data presented as AU/g and scaled by 106 
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Supplemental Tables 
 
Supplemental Table 2-1: Femur and tibia mass data (in grams) 
 
 
Femur 
 Proximal Diaphysis Distal Total 
Animal Right Left Right Left Right Left Right Left 
1 0.32 0.38 0.32 0.33 0.33 0.27 0.98 0.98 
2 0.54 0.46 0.42 0.52 0.49 0.57 1.45 1.55 
3 0.61 0.46 0.37 0.41 0.6 0.59 1.59 1.46 
4 0.51 0.48 0.46 0.48 0.51 0.5 1.49 1.46 
5 0.53 0.47 0.46 0.51 0.48 0.47 1.47 1.44 
Tibia 
 Proximal Diaphysis Distal Total 
Animal Right Left Right Left Right Left Right Left 
1 0.27 0.28 0.27 0.28 0.15 0.15 0.69 0.72 
2 0.23 0.3 0.29 0.28 0.13 0.12 0.65 0.71 
3 0.37 0.36 0.4 0.39 0.13 0.16 0.91 0.91 
4 0.32 0.39 0.36 0.34 0.15 0.16 0.83 0.9 
5 0.44 0.42 0.42 0.36 0.16 0.19 1.02 0.97 
 
Mass data presented in grams.  
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CHAPTER 3 
SKELETAL VASCULAR PERFUSION IS ALTERED IN CHRONIC KIDNEY 
DISEASE 
Introduction 
Patients with chronic kidney disease (CKD) have accelerated bone loss, 
vascular calcification and abnormal biochemistries. Together, these factors 
contribute to patients being at an alarming risk of cardiovascular disease and 
fracture-associated mortality [167]. In CKD patients, the risk of cardiovascular 
disease is increased 3 to 100-fold [168] and the risk of fracture 4 to 14-fold [169]  
compared to the normal population. These risks rise progressively as kidney 
function deteriorates. More striking, cardiovascular disease accounts for nearly 
60% of deaths in those with CKD (compared to 28% in the normal population); 
similarly over 60% of CKD patients that sustain a hip fracture die within a year 
(compared to 20% in the normal population) [2]. These striking statistics 
emphasize the critical need to better understand the underlying mechanism 
driving altered cardiovascular and skeletal homeostasis, as well as any potential 
connection between the two.  
 Bone is a highly vascularized tissue and bone perfusion plays a crucial 
role in bone growth [75], fracture repair [76-78], and bone homeostasis [79,80]. 
Disturbances to bone blood flow have been shown to have associated effects on 
bone health and function [79,82-85].  Conditions that alter bone remodeling 
(diabetes, disuse, aging, estrogen withdrawal, anabolic drug treatment) have all 
been associated with changes in bone blood flow [82,83,86-91]. Moreover, 
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disturbances to bone vasculature, due to any of a number of causes, result in 
alterations in tissue perfusion [92] and often bone loss [93]. CKD-induced 
elevations in uremic toxins have long been associated with vascular dysfunction 
of multiple arterial beds through endothelium-dependent, endothelium-
independent and/or vascular remodeling mechanisms [139-142]. In patients with 
CKD, decreased cardiac output [129], vascular calcification [130], and endothelial 
dysfunction [131-133] could all contribute to altered end-organ perfusion. 
Surprisingly data describing alterations in skeletal vascular perfusion in the 
setting of CKD are lacking. 
 The goal of the present study was to test the hypothesis that skeletal 
perfusion is altered in the setting of CKD. To accomplish this goal, we utilized 
fluorescent microspheres, which lodge in tissue capillaries in direct proportion to 
the fraction of cardiac output perfusing the tissue. This technique has been  
shown to allow measurement of organ perfusion as effectively as radioactive 
microspheres [122], the experimental gold standard [80], and has recently been 
applied to study skeletal perfusion in rats [170]. 
 
Methods 
Animals 
 Male Cy/+ rats, Han:SPRD rats (n=12) with autosomal dominant 
polycystic kidney disease [171], and their unaffected (normal) littermates (n=12) 
were used for this study. Male heterozygous rats (Cy/ +) develop characteristics 
of CKD around 10 weeks of age that progress to terminal uremia by about 40 
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weeks. Our laboratory has demonstrated that this animal model recapitulates all 
three manifestations of CKD-Mineral and Bone Disorder (CKD-MBD) - 
biochemical abnormalities, extraskeletal calcification, and abnormal bone 
[72,73,171]. There are many other animal models of the systemic repercussions 
of kidney disease, but unlike the Cy/+ model, most animal models of CKD are 
either acute injury or developmental/growth alterations and do not model the 
effect of the progressive nature of CKD on mineral metabolism. The model 
utilized in the current study (the Cy/+ rat) avoids this drawback. All animals were 
fed a casein diet (Purina AIN-76A, Purina Animal Nutrition, Shreevport, LA, 
USA); 0.53% Ca and 0.56% P) from 24 weeks on during the experiment, which 
has been shown to produce a more consistent kidney disease in this model 
[171]. Blood was collected ~24 hours prior to the end of the study for 
measurement of plasma biochemistries.   All procedures were reviewed and 
approved by the Indiana University School of Medicine Institutional Animal Care 
and Use Committee prior to study initiation. 
 
Experiments 
 CKD animals and their normal littermates were used in two separate 
studies, designed to assess alterations in two distinct time points along the 
progression of disease in the Cy/+ model: 
Experiment 1 – 30 week time point (~25% normal kidney function). Normal (NL) 
and Cy/+ (CKD) animals (n=6/group) were assessed for serum biochemistries ~ 
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one day before undergoing in vivo microsphere injection to assess bone tissue 
perfusion. 
Experiment 2 – 35 week time point (~15% normal kidney function). Normal (NL) 
and Cy/+ (CKD) animals (n=6/group) were assessed for serum biochemistries ~ 
one day before undergoing in vivo microsphere injection to assess bone tissue 
perfusion. 
 These two separate experiments aimed to describe skeletal perfusion at 
30 and 35 weeks were designed based on previous work demonstrating 
significant progression of skeletal disease in this timeframe [156,157]. While 
elevations in blood urea nitrogen (BUN) are noted by 25 weeks, progressive 
hyperphospatemia, hyperparathyroidism, and skeletal abnormalities become 
evident by 30 weeks. Between 30 and 35 weeks there is marked progression of 
all of the end organ manifestations of CKD-MBD, including left ventricular 
hypertrophy, cardiac and vascular calcification, and severe high turnover bone 
disease evident by severe cortical porosity, high turnover and compromised 
mechanical properties [156,157,172,173].  
 
Bone perfusion measurement 
 Microsphere injection was performed as previously described [170]. 
Briefly, under isoflurane anesthesia, polystyrene red fluorescent (580/605), 15 
µm microspheres (FluoSpheres, ThermoFisher) were injected into the apex of 
the beating left ventricle after opening the chest cavity. The spheres were 
allowed to circulate for 60 seconds before the animal was euthanized by cardiac 
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dissection. A total of 5.0x106 spheres/kg were injected, a number sufficient to 
assess perfusion in skeletal tissue [170].  
  Tibiae, femora, humeri, vertebrae (L4 body), kidneys and testes were 
collected and weighed. Testes were used as a positive control for assessing 
adequacy of microsphere delivery within each animal. Microsphere mixing and 
injection was considered adequate for an animal when right and left testicle 
perfusions were within 25% of each other. On the basis of this criterion, no 
animals were excluded from the study. Femur samples were divided into 
proximal, middle (diaphysis), and distal segments as previously described [83], 
and weighed separately.  Right femoral diaphysis marrow was left intact in bone 
while left femoral diaphysis marrow was thoroughly flushed and femoral cortex 
was weighed. Marrow was extracted from the tibial diaphysis by centrifugation; 
both marrow and tibial cortex were weighed. Marrow was left intact in the 
remainder of all specimens.  
 Bone samples were placed in individual amber vials with 15mL of Cal-Ex 
Decalcifier solution. After 7 days, decalcified bone samples were placed in 10% 
ethanolic postassium hydroxide (KOH) for degradation. Soft tissue samples 
(kidney and testes) were placed in KOH directly. After 24 hours of degradation, 
samples were vortexed to complete the degradation process and then filtered 
through polyamide mesh filters (5 µm pore size). 1mL of Cellosolve acetate (2-
ethoxyethyl acetate, 98%, Sigma) was added to each of the filtered samples to 
dissolve the microspheres and expose the fluorescence. The 24 hour KOH 
degradation step differed from the original protocol [170], where samples were 
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degraded in KOH for 48 hours. This slight alteration was made based on 
developmental work in our lab showing 24 hours was sufficient for degradation 
with longer durations causing progressive decline in fluorescence. 
  All fluorescence measurements were made using the SpectraMax i3x 
microplate reader (Molecular Devices, CA). Three 100µL aliquots from each 
sample were placed in a 96-well V-bottom polypropylene microplate for 
fluorescence quantification. The readings from the three aliquots were averaged 
to produce a single fluorescence measurement per sample. Red fluorescence 
was measured using an excitation of 580nm and an emission of 620nm. 
Standard curves of serial dilutions with known amounts of microspheres were 
generated on the day of analysis. Fluorescent measurements of samples found 
to be outside the standard curve (kidneys) were serially diluted and measured in 
order to detect any potential quenching effects. All data is presented as tissue 
fluorescence density (TFD) with units of Arbitrary Units per gram of tissue (AU/g) 
and scaled by 106.   
 
Biochemistries  
 Blood plasma was analyzed for blood urea nitrogen (BUN) and calcium 
using colorimetric assays (BioAssy System, DIUR-100). Intact PTH was 
determined by ELISA (Immutopics, REF-60-2500).   
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Statistical Analysis 
 All analyses were performed using GraphPad Prism software. Student’s t-
tests were used to compare CKD and NL groups within each experiment. 
Pearson product correlations were used to assess relationships between BUN, 
PTH and tissue perfusion. A priori a-levels were set at 0.05 to determine 
statistical significance. 
 
Results 
Experiment 1: 30 week data 
 There was no significant difference in body or bone mass between the two 
groups of animals (Supplemental Tables 3-1 and 3-2). Kidney mass was 
significantly higher in CKD due to cystic disease compared to age-matched 
normal littermates (NL) (Supplemental Tables 3-2). Plasma BUN, but not PTH, 
was significantly higher in CKD compared to age-matched normal littermates 
(NL), the former being consistent with reduced kidney function (Table 3-1). TFD 
was significantly higher in the femoral cortex (+259%, p<0.05) (Figure 3-1A) but 
not the tibial cortex (+140%, p=0.11) (Figure 3-1B) of CKD animals relative to 
NL. Isolated tibial marrow perfusion showed a trend toward being higher (+183%, 
p=0.08) in CKD compared to NL (Figure 3-1C). Vertebral body TFD was 
significantly higher in CKD animals (+116%, p<0.05) while neither distal femur 
(+109%, p=0.18) or humerus (+136%, p=0.08), significantly differed between 
groups (Figure 3-1E-G). These three bone sites all had intact marrow. Kidney 
perfusion was not significantly different in CKD animals when compared to their 
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normal littermates at 30 weeks (p=0.06) (Supplemental Table 3-3). There were 
no scientifically significant correlations between PTH and TFD for either NL or 
CKD animals (data not shown). 
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Table 3-1: Serum biochemistries 
Experiment 1 – 30 Weeks 
 NL CKD 
BUN, (mg/dL) 19.1 ± 1.7 39.7 ± 6.0* 
PTH, (pg/mL) 376 ± 298 420 ± 378 
Experiment 2 – 35 Weeks 
 NL CKD 
BUN, (mg/dL) 17.8 ± 1.9 50.4 ± 8.0* 
PTH, (pg/mL) 123 ± 49 1305 ± 237* 
 
Data presented as mean and standard deviation.  *p<0.05 
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Experiment 2: 35 week data 
 Animal body mass was significantly lower in CKD (-15%) compared to NL 
animals (Supplemental Table 3-1). Kidney mass was significantly higher and 
femoral diaphysis (with marrow) mass was significantly lower in CKD compared 
to age-matched normal littermates (NL) (Supplemental Table 3-2). Plasma BUN 
and PTH were both significantly higher in CKD compared to NL (Table 3-1). TFD 
in CKD animals was significantly higher in both the femoral cortex (+173%, 
p<0.05) (Figure 3-2A) and the tibial cortex (+241%, p<0.05) (Figure 3-2B) 
relative to NL. Isolated tibial marrow TFD was significantly lower (-57%, p<0.05) 
in CKD animals when compared to age-matched normal littermates (Figure 3-
2C). Vertebral body perfusion (-71%, p<0.05) was significantly lower in CKD 
animals compared to NL while neither distal femur (-27%%, p=0.17) or humerus 
(-10%, p=0.95) perfusions, both with marrow intact, were significantly different 
between groups (Figure 3-2E-G). Kidney perfusion was significantly lower in 
CKD animals when compared to their normal littermates (p<0.05) (Supplemental 
Table 3-3). There was no significant correlation between PTH and TFD for any 
site in the NL animals while 4 of the 6 sites assessed for TFD had significant 
negative relationships with PTH values (Table 3-2). 
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Table 3-2: 35 week correlations between PTH and tissue fluorescence density 
 
Femoral 
Cortex 
TFD 
Tibial 
Cortex 
TFD 
Tibial 
marrow 
TFD 
Distal 
femur  
TFD 
L4 
TFD 
Humerus 
TFD 
PTH 
(NL) 0.337 -0.264 -0.617 0.294 0.465 0.465 
PTH 
(CKD) -0.764 -0.772 0.338 -0.888 0.653 -0.724 
 
Data presented at r values with bolded values indicating p < 0.05. 
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Figure 3-1: 30 week time point bone perfusion data (n=6/group). Tissue 
fluorescence density (TFD) of (A) femoral cortical bone (p<0.05) (B) tibial cortical 
bone (p=0.11) (C) tibial bone marrow (p=0.08) (D) femoral diaphysis including 
marrow (p<0.05) (E) L4 vertebral body (p<0.05) (F) humerus (p=0.08) and (G) 
distal femur (p=0.18). Dots represent data points, and error bars represent 
standard deviation.  
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Figure 3-2: 35 week time point bone perfusion data (n=6/group). Tissue 
fluorescence density (TFD) of (A) femoral cortical bone (p<0.05) (B) tibial cortical 
bone (p<0.05) (C) tibial bone marrow (p<0.05) (D) femoral diaphysis including 
marrow (p<0.05) (E) L4 vertebral body (p<0.05) (F) humerus (p=0.95)  and (G) 
distal femur (p=0.17).  Dots represent data points, and error bars represent 
standard deviation. 
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Discussion 
 Deterioration of both bone and cardiovascular properties have been well 
documented during the progression of CKD. Bone is a highly vascularized tissue 
that depends on regulated perfusion for growth, repair, and homeostasis [81] . 
Since CKD is known to be associated with both cardiac and vascular 
abnormalities, the investigation of skeletal perfusion in the setting of CKD could 
provide insights into the pathophysiology of abnormal bone in CKD. The current 
study demonstrates two findings regarding bone perfusion in an animal model of 
high turnover CKD. First, cortical bone perfusion is higher than it is in animals 
with normal kidney function. Second, changes in bone marrow perfusion are 
more complex than those of bone, with higher perfusion early in disease and 
lower levels with prolonged/late stage disease. The differential changes in bone 
and marrow perfusion likely account for the more modest differences between 
CKD and NL in bone segments containing both tissues (Figures 3-1 and 3-2). 
The opposite trends of cortical bone and bone marrow and the proportional 
amount and type of marrow in each of the tested whole bones may play a role in 
the unclear trend observed in whole bone at 35 weeks.  
 Using fluorescent microspheres to measure regional bone perfusion, we 
show that animals with high turnover CKD have higher cortical bone perfusion at 
both 30 and 35 weeks compared to normal. Despite evidence of vascular 
pathologies in the current model [171-173] and known vascular dysfunction in 
CKD [15,144,145], we show that cortical bone perfusion in isolated femoral and 
tibia cortical bone diaphyses is nonetheless higher. We hypothesize that this 
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elevated cortical perfusion is due to one, or a combination, of two separate 
mechanisms. Cortical perfusion may be increased in response to increased 
metabolic needs of high turnover CKD bone, necessitating endothelial cells to 
express vasoactive substances that increase tissue blood flow [174]. 
Alternatively, PTH has been shown to have direct effects on the endothelial 
expression of vascular endothelial growth factor [175] such that worsening 
secondary hyperparathyroidism could be driving increased perfusion.  
 Conditions that alter bone remodeling (diabetes, disuse, aging, estrogen 
withdrawal, anabolic drug treatment) have all been associated with changes in 
bone blood flow [82,83,86-91]. Previous work has demonstrated that changes in 
perfusion can precede alterations to bone structure and function in these models. 
Increased perfusion occurs prior to fatigue loading-induced addition of bone 
mass [176]. By 30 weeks in this model Cy/+ rats have significant elevations in 
bone remodeling on trabecular bone surfaces whereas by 35 weeks they not only 
have high remodeling but also significant increases in intracortical remodeling 
and peritrabecular fibrosis. Previous work from our group suggests the escalation 
of skeletal deterioration in terms of increased turnover, impaired mechanics, 
cortical porosity, loss of cortical mass, and increased marrow fibrosis in the Cy/+ 
rat model between the two time points evaluated in this study – 30 and 35 weeks 
[157,177]. Further investigations will be needed to determine whether blood flow 
changes are driven by metabolic demands in CKD and whether these drive the 
skeletal phenotype (cortical porosity) or whether the bone and/or marrow 
changes alter the vascular perfusion.    
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 In the setting of CKD, we and others have shown that sustained elevated 
PTH contributes to high bone remodeling which drives increases in cortical 
porosity and ultimately compromised bone mechanics [156,157] but its 
contribution in vascular perfusion in CKD is unknown.   The direct role of PTH in 
modulating vasculature, including that of the bone, has been well-established in 
the literature [91,110,158,159]. Early studies illustrated the acute effects of 
intravenous injection of PTH to increase tibial and femoral perfusion within 30 
minutes after administration of intravenous PTH [178]. This suggested a 
vasodilatory effect that was confirmed in a recent study that showed PTH 
enhanced endothelium-dependent vasodilation of the femoral principal nutrient 
artery via augmented nitric oxide production [90].  Both of these studies 
represent acute PTH, and the effects of chronic elevation of PTH as seen in CKD 
may be different, given the divergent effects of intermittent and continuous PTH 
on bone mass. Roche et al found intermittent PTH stimulated bone formation and 
prevented OVX-induced reduction in bone perfusion and bone vessel density, 
while continuous PTH resulted in a decrease in vessel size [110]. Another study 
showed that treatment with teriparatide resulted an increase in bone blood flow, 
evaluated for up to 18 months [155]. Our correlation analysis of PTH and tissue 
perfusion resulted in an unexpected strong negative relationship between PTH 
and tissue perfusion across multiple bones.  While these data cannot speak to 
cause/effect, they provide a basis for future hypotheses that can fuel studies 
aimed at dissecting the role of PTH levels in CKD-related skeletal perfusion 
changes.  
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 Patterns of marrow perfusion (marrow having been extracted from the 
diaphyseal region only) in CKD animals diverged from those of cortical bone in 
late-stage high turnover disease. Although CKD animals show no change to 
marrow perfusion (trending towards higher) in the 30 week time point there was 
significantly lower perfusion at 35-weeks compared to NL animals. This is in 
contrast to cortical bone perfusion which was significantly higher in CKD animals 
at both of the time points. Previous work from our group has demonstrated lower 
levels of VEGF-A expression in bone marrow of 35-week old CKD animals 
compared to their normal littermates [107]. These suggest there may either be a 
dramatic shift in marrow VEGF signaling or marrow content during the later-stage 
manifestation of CKD.  Given the known fibrosis that occurs with the severe 
hyperparathyroid bone disease osteitis fibrosis cystica this may have decreased 
the overall non-fibrotic marrow in the 35 weeks animals. An alternative 
explanation is that more severe cardiac dysfunction due to heart calcification or 
aorta calcification may limit the ability to perfusion distal organs such as bone at 
late stage CKD [173].   
 Our results should be interpreted in the context of various assumptions 
and limitations. Injection of microspheres in the left ventricle to assess perfusion 
is based on a set of assumptions, including: microspheres are homogeneously 
distributed in the left ventricle, trapped in capillaries on first passage with no 
shunting or dislodging, and do not themselves alter the hemodynamics upon 
injection. This is the same set of assumptions made in any blood flow 
measurement using microspheres, the current experimental gold standard for the 
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determination of skeletal perfusion. A recovery standard was not utilized in order 
to ensure that sample is not lost during processing.  The animals are 
anesthetized using isoflurane, which is known to affect organ perfusion [165] and 
cardiovascular dynamics [166]. Without the use of assisted ventilation, the open-
chest cardiac injection of microspheres is performed under diminishing 
physiologic hemodynamic, as well as hypoxic, conditions. Given that the time 
from anesthesia to injection is consistent in experiments at each time point, and 
the injected spheres are fully circulated within the 60 seconds between injection 
and euthanasia, declining kidney function is not a major factor in the differences 
detected by our perfusion measurements.  
In conclusion, we have shown that bone perfusion is altered in an animal 
model of progressive high turnover chronic kidney disease. Determining whether 
these changes in bone perfusion are drivers, propagators, or consequences of 
skeletal deterioration in CKD will necessitate further work. 
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Supplemental Tables 
 
Supplemental Table 3-1: Body Masses 
 30 weeks 35 weeks 
NL CKD NL CKD 
Body Mass 
(grams) 
541.3 ± 34.7 531.8 ± 15.1 590.2 ± 34.1 500.5 ± 
68.5* 
Data presented as mean and standard deviation.  *p<0.05 
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Supplemental Table 3-2: Tissue Masses  
 Tissue Mass  
 30 weeks 35 weeks 
NL CKD NL CKD 
Kidney (grams) 1.95 ± 0.10 3.27 ± 0.22* 1.79 ± 0.31 3.69 ± 1.07* 
Tibial Cortex 
(grams) 
0.19 ± 0.01 0.19 ± 0.02 0.21 ± 0.02 1.79 ± 0.31 
Tibial Marrow 
(grams) 
0.029 ± 0.01 0.031 ± 0.01 0.039 ± 0.01 0.038 ± 
0.01 
Femoral Cortex 
(grams) 
0.34 ± 0.03 0.32 ± 0.04 0.28 ±  0.04 0.31 ± 0.02 
Femoral 
Diaphysis (with 
marrow) (grams) 
0.36 ± 0.02 0.35 ± 0.02 0.36 ±  0.02 0.31 ± 0.03* 
Distal Femur 
(grams) 
0.62 ± 0.03 0.63 ± 0.04 0.69 ±  0.04 0.65 ±  0.07 
L4 – Vertebral 
Body (grams) 
0.28 ± 0.04 0.25 ± 0.02 0.23 ±  0.05 0.23 ±  0.02 
Humerus 
(grams) 
0.72 ± 0.03 0.71 ± 0.04 0.73 ±  0.05 0.71 ±  0.23 
 
Data presented as mean and standard deviation.  *p<0.05 
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Supplemental Table 3-3: Kidney Perfusion 
 30 weeks 35 weeks 
NL CKD NL CKD 
Kidney Perfusion 
(TFD) 
562.5 ± 
424.8 
178.2 ± 
106.0 
1039.7 ± 
259.3 
66.1 ± 32.3* 
 
Data presented as mean and standard deviation.  *p<0.05; TFD = tissue 
fluorescent density (AU/grams) 
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CHAPTER 4 
SUPPRESSION OF PARATHYROID HORMONE NORMALIZES CHRONIC 
KIDNEY DISEASE-INDUCED ELEVATIONS IN CORTICAL BONE VASCULAR 
PERFUSION 
Introduction 
 Chronic kidney disease–mineral and bone disorder (CKD-MBD), 
consisting of  accelerated bone loss, vascular calcification, and abnormal 
biochemistries [179], contributes to an increased risk of premature death due to 
cardiovascular disease and fracture-associated mortality [167]. Understanding 
the underlying mechanisms of cardiovascular and skeletal alterations due to the 
sequelae of reduced kidney function, including mechanisms that overlap between 
cardiovascular and skeletal alterations, is crucial to developing novel ways to 
reduce mortality in CKD patients.  
 Patients with CKD have vascular dysfunction through endothelium-
dependent, endothelium-independent, and/or vascular remodeling mechanisms 
[139-142], along with decreased cardiac output [129], and vascular calcification 
[130], suggesting that altered skeletal perfusion can be expected in CKD. Bone 
health and homeostasis are dependent on regulated skeletal perfusion [81] and 
conditions that result in altered bone perfusion have been shown to be 
associated with bone loss [93]. Data from our lab have shown that cortical bone 
perfusion is elevated in a rat model of chronically high parathyroid hormone 
(PTH), high remodeling CKD [106]. However, whether vascular dysfunction and 
the bone abnormalities are related in CKD is not known.  
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 Sustained elevation of serum PTH in the setting of CKD has been shown, 
by our group and others, to contribute to compromised bone quantity and quality 
via elevated bone turnover and increased cortical porosity [156,157]. Currently, 
the primary goal of CKD-MBD therapy is the suppression of elevated levels of 
PTH [180] utilizing calcitriol (and its analogues) and calcimimetics. Our group has 
previously shown that the suppression of PTH levels with calcium 
supplementation in drinking water in rodents substantially mitigates the 
deleterious effects of CKD on bone parameters, essentially normalizing bone 
turnover and mass [181,182]. Despite the consistent suppression of PTH levels 
and the positive skeletal effects, calcium supplementation has been shown to 
increase vascular calcification [157] and, therefore, is not a viable therapeutic 
option. Calcimimetics, such as the recently FDA-approved etelcalcitide, suppress 
PTH without contributing to increased vascular calcification in rodents [183]. For 
this reason, the present study utilizes both calcium supplementation and a 
calcimimetic to evaluate the effect of PTH suppression on cortical bone 
perfusion.  We hypothesized that suppression of PTH would normalize CKD-
induced elevations in cortical bone perfusion.  
 
Methods 
Animals 
 Male Cy/+ (CKD) rats, Han:SPRD rats are characterized with a 
spontaneous and slowly progressive kidney disease [171]. Blood urea nitrogen 
(BUN) and creatinine are elevated by 10 weeks of age. With progression of CKD, 
62 
hyperphospatemia, hyperparathyroidism, and skeletal abnormalities develop and 
ultimately progress to dramatic manifestations of cardiac and vascular 
calcification as well as severe cortical porosity and compromised bone 
mechanical properties [72,73].  
 
Experimental Design 
Experiment 1:  
 CKD animals (n=12) and their normal littermates (NL, n=6) were used to 
assess alterations in skeletal perfusion at 35 weeks of age (~15% normal kidney 
function in the Cy/+ model). The CKD treatment animals were divided into two 
groups (n=6/group) at 25 weeks of age: half were administered normal deionized 
drinking water (CKD) and the other half administered calcium gluconate (3% Ca) 
in the drinking water (CKD+Ca). The calcium gluconate was used as a 
phosphate binder with the goal of PTH suppression as shown previously [157]. 
Age-matched normal (NL) littermate animals (n=6) were used as a comparator 
group to determine if treatment normalized skeletal perfusion. All animals were 
fed a casein diet (Purina AIN-76A, Purina Animal Nutrition, Shreevport, LA, 
USA); 0.53% Ca and 0.56% P) during the experimental period (weeks 25-35), 
which has been shown to produce a more consistent kidney disease in this 
model [171]. At 35 weeks, all animals were assessed for serum biochemistries 
approximately 24 hours before undergoing in vivo microsphere injection to 
assess bone tissue perfusion. Tibiae, femora, and testes were collected for 
analyses.  
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Experiment 2:  
 In order to differentiate the effects of PTH lowering from that of increased 
calcium intake, CKD animals (n=6) and their normal littermates (n=4) were used 
to assess the effect of KP-2326 (KP), an active metabolite of the calcimimetic 
etalcalcitide, on CKD-induced alterations in skeletal perfusion. The CKD 
treatment groups (n=3/group) were administered either vehicle injections thrice 
weekly or KP injection thrice weekly (i.p. 1mg/kg) from age 25 to 35 weeks. At 35 
weeks, all animals were assessed for serum biochemistries approximately 24 
hours before undergoing in vivo microsphere injection to assess bone tissue 
perfusion. Tibiae were collected for analysis.  
 
Plasma Biochemistries 
 Blood plasma was analyzed for blood urea nitrogen (BUN), calcium, 
phosphorus, and creatinine using colorimetric assays (Point Scientific, Canton, 
MI, USA; or Sigma kits; Sigma, St. Louis, MO, USA). Intact PTH was determined 
by ELISA (Alpco, Salem, NH, USA).  
 
Bone perfusion measurement 
 Microsphere injection was performed as we previously described [170]. 
Briefly, under isoflurane anesthesia, polystyrene red fluorescent (580/605), 15 
µm microspheres (FluoSpheres, ThermoFisher) were injected into the apex of 
the beating left ventricle. The animal was euthanized by cardiac dissection 60 
seconds after the completion of the injection, allowing for the circulation of 
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spheres. A total of 5.0x106 spheres/kg were injected, a number sufficient to 
assess perfusion in skeletal tissue [170].  
  Tibiae, femora, and testes were collected and weighed. Microsphere 
mixing, injecting, and delivery of microspheres were considered adequate for an 
animal when right and left testicle perfusions were within 25% of each other. On 
the basis of this criterion, no animals were excluded from experiment 1 and 
testes collection/analyses were deemed unnecessary for experiment 2. Femoral 
diaphyses were isolated, thoroughly flushed of marrow, and weighed. Marrow 
was extracted from the tibial diaphysis by centrifugation; both marrow and tibial 
cortex were weighed. In Experiment 2, only the tibia was collected for perfusion 
analysis. The tibial cortex was isolated and marrow was separated by 
centrifugation.  
 Samples isolated for tissue perfusion measures were processed as 
previously described [170]. Briefly, bone samples were placed in a Cal-Ex 
Decalcifier solution for 7 days. Decalcified bone samples were degraded in 10% 
ethanolic potassium hydroxide (KOH) for 24 hours. Soft tissue samples (testes) 
were placed in KOH directly. Degraded samples were filtered through polyamide 
mesh filters (5 µm pore size) and placed into microcentrifuge vials along with 
1mL of Cellosolve acetate (2-ethoxyethyl acetate, 98%, Sigma) to dissolve the 
microspheres and distribute the fluorescence into solution.  
 Fluorescence measurements were performed as previously described 
[170]. Briefly, three 100µL aliquots from each sample were placed in a 96-well V-
bottom polypropylene microplate for fluorescence quantification using the 
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SpectraMax i3x microplate reader (Molecular Devices, CA). The readings from 
the three aliquots were averaged to produce a single fluorescence measurement 
per sample. Red fluorescence was measured using an excitation of 580nm and 
an emission of 620nm. All data is presented as tissue fluorescence density (TFD) 
with units of Arbitrary Units per gram of tissue (AU/g) and scaled by 106.   
 
μCT Imaging 
 Tibiae were scanned (Skyscan 1172, 6 micron resolution) to obtain 
cortical morphology at a standardized location (~2.5mm distal to the proximal 
growth plate). Cortical parameters included total cross-sectional area, bone area, 
marrow area, cortical thickness, and cortical porosity. Porosity was calculated as 
the percent of void area within the total cross sectional area (100 – BA/TA*100). 
Nomenclature is reported in accordance with ASBMR guidelines [184]. 
 
Statistics  
 All analyses were performed using GraphPad Prism software. 
Comparisons among groups were assessed by Kruskal-Wallis analysis of ranks 
with Dunn’s multiple comparisons post-hoc tests when appropriate. A priori α-
levels were set at p < 0.05 to determine statistical significance.  
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Results 
Plasma Biochemistries 
Experiment 1: 
 Animals with CKD had serum blood urea nitrogen (BUN) and PTH levels 
that were significantly higher than NL (+182% and +958%; p<0.05) (Table 4-1). 
CKD+Ca animals had BUN levels that were not different from CKD (p=0.7922), 
while PTH levels were significantly lower than CKD alone (p=0.004) and not 
different from NL (Table 4-1). 
Experiment 2: 
 Animals with CKD had elevated serum blood urea nitrogen (BUN) and 
PTH levels compared to NL (+119% and +2700%), although due to variability 
and low sample size, the results did not reach statistical significance (Table 4-1). 
CKD+KP animals had BUN levels that were not different from CKD, while PTH 
levels were lower than CKD alone and not different from NL (Table 4-1). 
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Table 4-1: Serum biochemistries at end point (35 weeks) 
Experiment 1 
 Normal CKD CKD+Ca 
BUN (mg/dL) 17.8 ± 1.9* 50.4 ± 8.0 49.1 ± 9.4 
PTH (mg/dL) 123 ± 49 2105 ± 139* 33 ± 42 
Experiment 2 
 Normal CKD CKD+KP 
BUN (mg/dL) 20.8 ± 1.8 45.7 ± 2.6 51.2 ± 8.7 
PTH (mg/dL) 263 ± 66 6840 ± 6935 403 ± 265 
 
Data presented as mean and standard deviation.  *p<0.05, different from all other 
groups 
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Bone geometry 
Experiment 1: 
 Cortical mean cross-sectional area (p=0.002) was significantly lower in 
CKD animals when compared to NL animals, while the calcium supplementation 
(CKD+Ca) group was not different from NL (Table 4-2). MicroCT analysis of the 
proximal tibia cortical porosity was higher in CKD (+401% vs. NL; p=0.017) and 
not different in CKD+Ca (+111% relative to NL; p = 0.38) (Table 4-2).   
Experiment 2: 
 MicroCT analysis of the proximal tibia demonstrated cortical porosity was 
significantly higher in CKD (+925%; p=0.05) vs. NL, but not different in CKD+KP 
(+42%; p = 0.86) animals relative to NL (Figure 4-1). Cortical mean cross-
sectional area (ANOVA, p=0.09) showed a trend toward lower values in CKD (-
20%; p=0.078) compared to NL while CKD+KP (-8%; p = 0.70) animals were not 
different compared to NL (Table 4-2). 
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Table 4-2: Proximal tibia cortical geometry  
Experiment 1 
 Normal CKD CKD+Ca 
Cortical Area 
(mm2) 
7.3 ± 0.2 6.1 ± 0.7* 7.1 ± 0.3 
Cortical Porosity 
(%) 
1.1 ± 2.0 5.7 ± 4.7 2.4 ± 2.3 
Experiment 2 
 Normal CKD CKD+KP 
Cortical Area 
(mm2) 
6.0 ± 0.3 4.8 ± 1.1 5.5 ± 0.1 
Cortical Porosity 
(%) 
2.8 ± 0.5 28.3 ± 22.25* 3.9 ± 2.2 
 
Data presented as mean and standard deviation.  *p<0.05, compared to Normal 
group 
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Figure 4-1: MicroCT of proximal tibia 2.5mm distal to the proximal growth plate  
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Bone perfusion measurement 
Experiment 1: 
 Femoral cortex (p=0.003) and tibial cortex (p=0.005) tissue perfusion were 
both significantly higher in CKD animals when compared to NL animals (Figure 
4-2A&B). PTH suppression via calcium supplementation resulted in femoral and 
tibial cortical perfusion that was not different than normal. Isolated marrow 
perfusion (p=0.005) was significantly lower in CKD animals when compared to 
NL animals (Figure 4-2C). PTH suppression via calcium supplementation 
resulted in isolated marrow perfusion with values not different from CKD animals 
receiving no treatment.  
Experiment 2: 
 Tibial cortex (p=0.05) tissue perfusion was significantly higher in CKD 
animals when compared to NL animals (Figure 4-2D). PTH suppression via KP 
treatment resulted in tibial cortical perfusion that was not different than normal.  
Isolated marrow perfusion showed a trend toward lower values in CKD (-63%; 
p=0.11) vs. NL, while CKD+KP were not different from NL (-26%; p = 0.40) 
(Figure 4-2E). 
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Figure 4-2: Bone perfusion data. Experiment 1: Tissue fluorescence density 
(TFD) of (A) femoral cortical bone (Kruskal-Willis, p=0.0030) (B) tibial cortical 
bone (Kruskal-Willis, p=0.0051) (C) tibial bone marrow (Kruskal-Willis, 
p=0.0047). Experiment 2: Tissue fluorescence density (TFD) of (A) tibial cortical 
bone (Kruskal-Willis, p=0.0505) (B) tibial bone marrow (Kruskal-Willis, p=0.0780). 
Dots represent data points, and error bars represent standard deviation. *p<0.05, 
different from all other groups 
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Discussion 
CKD causes progressive damage to bone. Bone deterioration in CKD can 
be characterized by changes in turnover, mineralization, and volume [179], 
where, most commonly, high turnover drives bone loss. Altered bone 
turnover/remodeling has been associated with changes in bone perfusion in a 
number of conditions including diabetes, disuse, aging, and estrogen withdrawal 
[82,83,86-91]. In turn, reduced bone perfusion has also been associated with 
bone loss in a number of conditions [93]. Since CKD is known to be associated 
with both cardiac and vascular abnormalities, we investigated skeletal perfusion 
in the setting of CKD to provide insights into the pathophysiology of skeletal 
changes in CKD.  
Previous studies, by our group and others, have shown that sustained 
elevation of serum PTH in the setting of CKD contributes to compromised bone 
quantity and quality [156,157].  In the present study, with the use of fluorescent 
microspheres to measure regional perfusion in bone, we show that PTH 
suppression, using two different approaches, normalizes CKD-induced elevations 
in cortical bone perfusion. CKD animals with calcium supplementation and 
calcimimetic treatment had PTH levels that were suppressed by 98% and 94% 
relative to untreated CKD animals, respectively, yielding PTH levels that were not 
significantly different than normal animals. Our group has previously shown that 
the suppression of PTH levels with calcium supplementation in drinking water 
has substantial positive skeletal effects, essentially normalizing bone turnover 
and volume [181,182]. In the present study, PTH suppression via calcium 
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supplementation or calcimimetic treatment resulted in higher cortical bone area 
along with normalized cortical bone perfusion (Figure 4-3A-B). It is unclear 
whether normalization of CKD-induced elevations in cortical bone perfusion via 
PTH suppression is secondary to normalized CKD-induced structural changes in 
bone, directly due to the effect of low PTH/low remodeling CKD on vasculature, 
or more likely, a combination of both (Figure 4-4). In other words, the 
normalization of cortical bone perfusion via PTH suppression suggests that 
perfusion elevations are either dependent on PTH, or dependent on a factor 
secondary to elevated PTH, such as increased cell metabolism. PTH 
suppression can reduce the direct effects of PTH on the endothelial expression 
of vascular endothelial growth factor [175] and consequently normalize CKD-
induced elevation in cortical bone perfusion. On the other hand, PTH 
suppression can result in the attenuation of the increased metabolic demands 
[174] of high turnover CKD secondary to elevated PTH levels.  
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Figure 4-3: Combined graphs with data from Experiments 1 & 2: (A) tibial cortical 
perfusion, (B) tibial cortical porosity, (C) tibial marrow perfusion   
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Figure 4-4: Potential mechanism of elevated PTH effect on cortical perfusion 
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The current study demonstrates lower marrow perfusion in the setting of 
high PTH/high remodeling CKD in two separate experiments that is not 
completely normalized with PTH suppression (Figure 3C). In addition to well-
described mineral disturbances and hormonal factors that influence osteoclast 
differentiation in CKD, osteoclast differentiation and activity may be further 
exacerbated by decreased marrow perfusion resulting in medullary hypoxia. 
Medullary hypoxia has been shown to induce osteoclast and inhibit osteoblast 
differentiation [81]. The lack of normalization of CKD-induced lowering of marrow 
perfusion in the low PTH/low remodeling CKD state suggests that marrow 
perfusion is not dependent on the high remodeling state in the setting of CKD. 
Other factors including arterial perfusion pressures, myogenic, endothelial, neural 
and hormonal disturbances may explain alterations of marrow perfusion in the 
setting of CKD.  Marrow hypoxia may also explain the relative suppression 
hypoxia inducible factor-1 (Hif-1) with suppression of PTH in the Cy/+ rats [107].  
Characterizations of bone circulation have confirmed that principal 
relationships of regulatory factors in the circulation of other tissues also apply to 
the vascular tissue in bone [128]. Thus regulation of cortical bone perfusion is 
dictated by a balance between oxygen delivery to cortical bone (supply) and 
metabolism of bone cells (demand). Mechanisms that help maintain this balance 
are arterial perfusion pressures, myogenic, local metabolic, endothelial, neural 
and hormonal influences. Despite the well-established evidence of vascular 
dysfunction in CKD [15,144,145], along with evidence of vascular pathologies in 
the Cy/+ rat model [171-173], data from our lab have shown that cortical bone 
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perfusion is elevated in the setting of high parathyroid hormone (PTH), high 
remodeling CKD  [106], in combination with lower marrow perfusion. Our working 
hypothesis is that increased cortical bone perfusion, in the setting of decreased 
delivery due to the known vascular dysfunction of CKD, is likely indicative of 
increased metabolism of cortical bone cells. The decrease of marrow perfusion in 
the setting of the increased metabolism due to increased bone turnover in CKD is 
likely indicative of decreased delivery to the marrow.  
 Our results should be interpreted in the context of various assumptions 
and limitations. Injection of microspheres in the left ventricle to assess perfusion 
is based on a set of assumptions and has multiple limitations as discussed in our 
previous work [170] [106]. While these limitations are important to consider from 
a technical standpoint, we have now consistently shown in several studies that in 
CKD in the setting of high PTH there is higher cortical perfusion. Another 
limitation of our current work is the low number of animals in Experiment 2. 
Although we did not have as many animals in Experiment 2, the results of PTH 
suppression due to calcimimetic treatment paralleled that observed with calcium 
induced suppression of PTH in that both treatments normalize cortical bone 
perfusion, without effect on marrow perfusion (Figure 2A-C), thus confirming that 
the effects are due to PTH suppression rather than the calcium treatment.    
The effect of CKD-induced perfusion elevations in cortical bone are 
normalized by reductions in PTH. The normalization of cortical bone perfusion via 
PTH suppression suggests that perfusion elevations are PTH dependent, either 
direct or indirectly mediated via another factor.  Determining the mechanisms of 
79 
these bone perfusion alterations and whether they are drivers, propagators, or 
consequences of skeletal deterioration in CKD will necessitate further work but 
will help untangle a key player in CKD-induced bone quality alterations. 
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CHAPTER 5 
EFFECTS OF CKD ON ISOLATED VESSEL PROPERTIES: PRELIMINARY 
INVESTIGATION 
Introduction 
Chronic kidney disease has negative effects on vascular reactivity and 
end-organ perfusion. In the setting of CKD, decreased cardiac output [129], 
vascular calcification [130], and endothelial dysfunction [131-133] could all 
contribute to altered end-organ perfusion. Hypoperfusion, in the setting of CKD, 
that causes ischemia has been illustrated in the myocardium [134], brain 
[135,136], and mesentery [137]. However, studies that elucidate the effect of 
individual cardiovascular pathologies on end-organ perfusion in CKD have yet to 
be performed. Moreover, CKD-induced elevations in uremic toxins including 
phosphate [138] and parathyroid hormone (PTH) [110] have long been 
associated with vascular dysfunction through endothelium-dependent, 
endothelium-independent and/or vascular remodeling mechanisms [139-142]. 
Extensive work in CKD has documented vascular changes to coronary vessels 
[143,144] and aorta [145,146]. Gastrointestinal resistance arteries, which control 
organ perfusion, have also been shown to be adversely affected in models of 
CKD [147-150]. Other work has illustrated structural remodeling of resistance 
arteries manifested as alterations in arteriolar wall thickness and lumen diameter 
[151,152]. Surprisingly, the effects of uremia, including elevations in PTH and 
phosphate, on skeletal vascular reactivity have not been studied. 
In vitro isolated vessel preparations can be used to characterize functional 
reactivity of vessels in settings of disease and in response to vasoactive agents. 
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Myography is an in vitro vessel preparation method that enables the 
characterization of the functional reactivity of vessels through the measurement 
of tension induced in isometric conditions (Wire Myography), or the measurement 
of changes in diameter under isobaric conditions (Pressure Myogrpaphy). In the 
current studies we isolate vessels from CKD animals and utilize wire myography 
to test vascular reactivity. The objective of these pilot studies is to work out 
methods and begin generating data to address the hypothesis that vascular 
reactivity is altered in the setting of chronic kidney disease.  
 
Methods 
Animals  
 Male Cy/+ rats, Han:SPRD rats (n=4) with autosomal dominant polycystic 
kidney disease [171], and their unaffected (normal) littermates (n=4) were used 
for this study. Male heterozygous rats (Cy/ +) develop characteristics of CKD 
around 10 weeks of age that progress to terminal uremia by about 40 weeks. Our 
laboratory has demonstrated that this animal model recapitulates all three 
manifestations of CKD-Mineral and Bone Disorder (CKD-MBD) - biochemical 
abnormalities, extraskeletal calcification, and abnormal bone [72,73,171]. 
Arteries (aorta and femoral artery) were harvested at 35 weeks after animals 
were euthanized. All procedures were reviewed and approved by the Indiana 
University School of Medicine Institutional Animal Care and Use Committee prior 
to study initiation. 
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Aortic wire myography  
Immediately following euthanasia (n=2) via aortic rupture under isoflurane, 
the abdominal aorta was removed and dissected into two 3-mm aortic rings. The 
aortic rings were then suspended and hooked to a force transducer in a warmed 
organ bath (37 ± 0.5°C) containing gassed (95% O2 and 5% CO2) physiological 
solution (in mM: NaCl 136.9, KCl 5.4, MgCl2 1.05, NaH2PO4 0.42, NaHCO3 22.6, 
CaCl2 1.8, glucose 5.5, ascorbic acid 0.28 and Na2EDTA 0.05). Smooth muscle 
cell contractile function was determined by a cumulative concentration-response 
curve to increasing concentrations of KCl (concentration 10mM to 60mM). 
Endothelial control of vascular relaxation (endothelium-dependent) was 
determined by adding the muscarinic agonist acetylcholine (concentration 10-9 to 
10-5 M) following a 70% submaximal pre-contraction to noradrenaline. The 
change in isometric force was measured using Grass FT03 force transducers 
(Grass, MA, USA) connected to a PowerLab chart recording system using Chart 
4.0 recording software (AD Instruments, Sydney, NSW, Australia).  Two aortic 
rings were tested per animal and average values were calculated resulting in one 
set of values per animal. Main outcomes of vascular reactivity were active 
tension (in grams) in response to potassium chloride and active relaxation 
(measured as % relaxation following 70% submaximal pre-contraction to 
noradrenaline) in response to acetylcholine by measuring contraction and 
relaxation with the force transducer of the wire myograph. 
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Femoral artery wire myography  
Immediately following euthanasia (n=2) via aortic rupture under isoflurane, 
the right femoral artery was removed, dissected, and divided into two 3-mm 
femoral artery segments. The femoral artery segments were mounted on two 40 
μm stainless steel wires in a myograph chamber (620M; Danish Myo 
Technology; Aarhus, Denmark) and kept in Krebs’ PSS at 37C (pH 7.4) with 
continuous aeration by a mixture of 95% O2 and 5% CO2. The distance between 
the wires was adjustable to set the passive force of the femoral artery segment 
before testing. One wire was connected to an isometric force transducer while 
the other was connected to a screw micrometer used for adjustment of passive 
force. Measurement of vascular contractile force was recorded on a computer 
using LabChart 7 software (AD Instruments, Pty. Ltd, Bella Vista, NSW, 
Australia). Smooth muscle cell contractile function was determined by a 
cumulative concentration-response curve to increasing concentrations of KPSS 
(concentration 10mM to 60mM). Endothelial control of vascular relaxation 
(endothelium-dependent) was determined by adding the muscarinic agonist 
acetylcholine (concentration 10-9 to 10-5 M) following a 70% submaximal pre-
contraction to KPSS. Main outcomes of vascular reactivity were active tension (in 
mN) in response to potassium chloride and active relaxation (measured as % 
relaxation following 70% submaximal pre-contraction to KPSS) in response to 
acetylcholine by measuring contraction and relaxation with the force transducer 
of the wire myograph.   
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Statistical analysis  
All data presented as mean ± SD. Active tension and active relaxation of 
NL and CKD arteries were compared statistically using unpaired t tests at each 
concentration of vasoactive agent. All statistical analysis was performed using 
GraphPad Prism 8.0 (GraphPad software, San Diego, CA, USA). A priori a-levels 
were set at 0.05 to determine significance. 
 
Results and Discussion 
KPSS (femoral wire myography) induced concentration-dependent 
contractile effects of CKD arteries that were attenuated at higher concentrations 
when compared to NL arteries (Figure 1A and 1C). Although a similar trend was 
observed in aortic wire myography, there was not statistical difference of CKD 
aorta active tension when compared to NL aortas. Acetylcholine induced a 
concentration-dependent relaxation of pre-contracted rat aortic rings and femoral 
arteries. While ACh-induced relaxation of CKD arteries was attenuated in the 
aorta (Figure 5-1B), ACh-induced relaxation of the femoral artery (Figure 5-1D) 
was not statistically different when compared to NL arteries. Altered mineral 
metabolism, inflammation, and oxidative stress have been identified as causative 
factors of vascular dysfunction in CKD [185]. Functional and morphological 
changes to vascular smooth muscle and endothelium impair vascular function 
[196]. One of these impairments of vascular function in CKD is the loss of 
contractile elements due to alterations of the vascular smooth muscle cell 
phenotype due to the uremia of CKD [196]. In the present study, we demonstrate 
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diminished active tension in both the aorta and the femoral artery in the setting of 
CKD, along with altered endothelial dependent relaxation.  
 
Figure 5-1: Aortic and femoral wire myography. Aortic wire myography (n=2) A) 
aortic active tension B) aortic endothelial-dependent relaxation.  Femoral artery 
wire myography (n=2) C) aortic active tension D) aortic endothelial-dependent 
relaxation.  Data presented as mean + SD.  
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In three separate experiments, we show lower bone marrow perfusion in 
CKD tibiae when compared to their normal littermates (Chapters 3&4). Altered 
perfusion can be a result of any one, or a combination of, disturbances to supply 
(vascular delivery or vascular volume), disturbances to demand (metabolic 
activity), or dysregulated signaling/pathology that affects the bone vascular 
network. Diminished marrow perfusion in the setting of CKD is likely due to a 
combination of disrupted vascular delivery secondary to vascular dysfunctions of 
CKD along with decreased metabolic demand due to decreased marrow 
cellularity and marrow cell function (Figure 5-2). This decreased marrow 
perfusion may result in diminished marrow cell function that may then further 
decrease metabolic demand and further decrease marrow perfusion. In other 
words, decreased marrow function as a consequence of decreased marrow 
perfusion may itself perpetuate decreased marrow perfusion. In the current pilot 
studies, we show that vascular reactivity is altered in both the aorta and the 
femoral artery in animals with progressive kidney disease, suggesting that 
diminished marrow perfusion may occur, at least partly, due to altered vascular 
reactivity and ultimately decreased blood supply.  
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Figure 5-2: Potential causes and consequences of decreased marrow perfusion.  
 
  
88 
The next steps in investigating the impact of altered vascular reactivity in 
the setting of CKD on bone perfusion are expanding the sample size in large 
vessel wire myography studies, quantifying alterations to bone vascular reactivity 
in CKD via isolated vessel experiments utilizing the principal nutrient artery of the 
femur, and performing isolated vessel wire myography experiments incorporating 
in vivo and ex vivo elevations of PTH to test the direct effects of high levels of 
PTH on vascular reactivity. Chronic elevations in parathyroid hormone (PTH) 
may drive altered bone vascular properties in CKD. In the setting of CKD, we and 
others have shown that sustained elevated PTH contributes to high bone 
remodeling which drives increases in cortical porosity and ultimately 
compromised bone mechanics [156,157]. Moreover, the role of PTH in 
modulating vasculature, including that of the bone, has been well-established in 
the literature [91,110,158,159]. The present study presents preliminary data 
utilizing the wire myography method to perform isolated vessel experiments that 
will enable the testing of our working hypothesis: elevated PTH drives 
maladaptive changes to the skeletal vasculature that contribute to the skeletal 
deterioration in CKD. 
The major limitation of the wire myograph method is that the function of 
these vessels was studied under conditions that remove myogenic, neural, 
hormonal, and metabolic factors, which are significant contributors to the 
regulation of vascular reactivity. However, wire myography is a well-accepted 
method in the field to test vascluar reactivity. Further studies can utilize pressure 
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myogrpahy in order to test myogenic responses, but removing neural, hormonal 
and metabolic factors is characteristic to isolated vessel experiments.  
In health, the main blood supply of the marrow originates from the nutrient 
artery, which originates from large arteries of the extremities (i.e femoral/tibial 
and brachial/radial arteries), penetrates the cortex and divides into ascending 
and descending branching running along the length of the bone within the 
medullary cavity [128]. The main nutrient artery running longitudinally through the 
medullary cavity will supply the medullary sinuses in the marrow along with 
cortical branches directed back toward the endosteum. Any disturbances to the 
vascular supply to the nutrient artery (including decreased vascular reactivity of 
large arteries) will result in decreased perfusion to the marrow.  The current study 
presents preliminary data that demonstrates altered vascular reactivity in both 
the aorta and the femoral artery in the setting of CKD, which may play a role in 
altered bone perfusion in CKD.  
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CHAPTER 6 
DISCUSSION 
Summary 
The objective of the current series of studies was to better understand the 
effects of CKD on maladaptive changes to skeletal perfusion that may contribute 
to the skeletal deterioration in CKD. Gaining a better understanding of the 
multiple factors that lead to bone structural and material deterioration in CKD is 
crucial to finding novel and effective therapy targets.  
Disturbances to bone perfusion have been shown to play a role in skeletal 
dysfunction in systemic and skeletal diseases [79,83-85,87] yet there remain 
many unanswered questions, due in part to the complexity of measurement 
methodologies  [80]. In Chapter 2, we fill this void by showing the viability of 
injection and analysis of fluorescent microspheres to assess regional bone tissue 
perfusion in rats. Although this technique has been documented with radioactive 
microspheres in rats, and using these fluorescent microsphere in mice, there 
necessitated significant technique development to apply fluorescent sphere 
measures in rats.  In Chapter 3, we utilize animals with progressive kidney 
disease and their normal littermates to assess alterations in skeletal perfusion at 
two different time points. Using the fluorescent microsphere protocol established 
in Chapter 1, we show that animals with high turnover CKD have higher cortical 
bone perfusion at both 30 and 35 weeks compared to non-diseased animals. 
Despite evidence of vascular pathologies in the current model [171-173] and 
known vascular dysfunction in CKD [15,144,145], we show for the first time that 
cortical bone perfusion in isolated femoral and tibia cortical bone diaphyses is 
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nonetheless higher. Also, most interestingly, in Chapter 3, we show that patterns 
of marrow perfusion in CKD animals diverged from those of cortical bone in late-
stage high turnover disease. Although CKD animals show no change to marrow 
perfusion (trending towards higher) in the 30 week time point there was 
significantly lower perfusion at 35-weeks compared to NL animals. In Chapter 4, 
with the goal of showing proof of principle that treatments could normalize tissue 
perfusion, we show that PTH suppression, using two different approaches, 
normalizes CKD-induced elevations in cortical bone perfusion. We also 
demonstrate that the lower marrow perfusion in high PTH/high remodeling CKD 
is not completely normalized with PTH suppression.  
Past literature has documented that regulation of bone perfusion is 
dictated by a balance between oxygen delivery to the bone (supply) and 
metabolism of cells in bone (demand). Altered perfusion can be a result of 
disturbances to supply (vascular delivery or vascular volume), demand 
(metabolic activity), or dysregulated signaling/pathology that affects the bone 
vascular network. In Chapter 5, we undertook preliminary investigation of blood 
delivery to bone upstream of cortex through measures of vascular reactivity of 
the aorta and the femoral artery. Using ex vivo wire myography, we were able to 
generate preliminary data to show that vascular reactivity is altered in both the 
aorta and the femoral artery in animals with progressive CKD.  
In summary, the novel findings of this work are: 1) cortical bone perfusion 
is elevated and bone marrow perfusion is lower in the setting of high PTH/high 
remodeling CKD; and 2) PTH suppression, using two different approaches, 
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normalizes CKD-induced elevations in cortical bone perfusion but not CKD-
induced depression in bone marrow perfusion. 
 
Understanding CKD-induced elevations in cortical bone perfusion 
Despite evidence of vascular pathologies in the current model [171-173] 
and known vascular dysfunction in CKD [15,144,145], we show that cortical bone 
perfusion in isolated femoral and tibia cortical bone diaphyses is nonetheless 
higher (Chapter 2). We hypothesize that this elevated cortical perfusion is due to 
one, or a combination, of two separate mechanisms. Cortical perfusion may be 
increased in response to increased metabolic needs of high turnover CKD bone, 
necessitating endothelial cells to express vasoactive substances that increase 
tissue blood flow [174]. Alternatively, PTH has been shown to have direct effects 
on the endothelial expression of vascular endothelial growth factor [175] such 
that worsening secondary hyperparathyroidism with sustained elevations in PTH 
could be driving increased perfusion.  
PTH suppression via calcium supplementation or calcimimetic treatment 
resulted in higher cortical bone area along with normalized cortical bone 
perfusion (Chapter 4). It is unclear whether normalization of CKD-induced 
elevations in cortical bone perfusion via PTH suppression is secondary to 
normalized CKD-induced structural changes in bone, directly due to the effect of 
low PTH/low remodeling CKD on vasculature, or more likely, a combination of 
both. In other words, the normalization of cortical bone perfusion via PTH 
suppression suggests that perfusion elevations are either dependent on PTH, or 
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dependent on a factor secondary to elevated PTH, such as increased cell 
metabolism. PTH suppression can reduce the direct effects of PTH on the 
endothelial expression of vascular endothelial growth factor [175] and 
consequently normalize CKD-induced elevation in cortical bone perfusion. On the 
other hand, PTH suppression can result in the attenuation of the increased 
metabolic demands [174] of high turnover CKD secondary to elevated PTH 
levels. In order to uncouple the effects of PTH and bone turnover on altered 
perfusion, future investigation will utilize a bisphosphonate to suppress only 
turnover and not PTH, and calcium supplementation to suppress both turnover 
and PTH (see Table 6-2 section 3a for more details). 
Previous studies have established the relationship between bone 
metabolic demand and bone remodeling rates. Sim and Kelly performed a study 
of vascular aspects of endocrinopathies and showed a weak but present 
relationship between oxygen consumption and bone remodeling in mature 
beagle bone [190]. Similarly, with the increased bone remodeling rates observed 
in high PTH/high remodeling CKD, there is also expected to be elevated oxygen 
consumption in the bone, and thus, increased metabolic demand, which would 
signal for increased perfusion to the bone. Concurrently, it is important to 
understand that hypoxia has been shown to stimulate bone resorption by 
accelerating the formation of osteoclasts and ultimately increasing osteoclast 
number [95], and bone resorption. In addition to well-described mineral 
disturbances and hormonal factors that promote osteoclast differentiation in 
CKD, marrow hypoxia may contribute to increased osteoclast differentiation, 
94 
ultimately resulting in increased cortical bone turnover and increased metabolic 
demand [81][191]. 
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Table 6-1: Bone perfusion, bone formation rate, and bone volume in different 
conditions  
Condition  Bone perfusion BFR Bone remodeling 
balance 
Bone 
volume 
Aging [87] Decreased (bone) 
Decreased 
(marrow) 
- Net negative Bone loss 
Diabetes [84] Decreased 
(marrow) 
Not measured 
(bone) 
-/low - - 
CKD [106] Increased (bone) 
Decreased 
(marrow) 
high Net negative Bone loss 
Unloading [83] Decreased (bone) 
Decreased 
(marrow) 
high Net negative  Bone loss 
Intermittent 
PTH [186] 
Increased (bone) 
Increased 
(marrow) 
high Net positive Bone gain 
Continuous 
PTH [110] 
No change 
(marrow)* Not 
measured (bone) 
high Net negative Bone loss 
*only 14 days of continuous PTH therapy 
AgingDiabetes CKD [106]Unloading  Intermittent PTH Continuous PTH  
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Table 6-1 summarizes the relationship between bone perfusion, bone 
remodeling rate, and bone volume in a number of conditions, including CKD. Net 
negative remodeling balance does not appear to directionally correspond to 
increased or decreased perfusion, but decreased marrow perfusion seems to 
directionally match with bone loss. So although increased metabolic demand 
secondary to increased cortical bone resorption may drive increased cortical 
bone perfusion, medullary hypoxia secondary to CKD-induced vascular 
dysfunction may contribute to the increased availability of active osteoclasts in 
the marrow. 
 
Understanding CKD-induced lowering of marrow perfusion 
In three separate experiments, we show marrow perfusion to be lower in 
CKD animals when compared to their normal littermates (Chapters 3&4). This is 
in contrast to cortical bone perfusion which was significantly higher in CKD 
animals at both of the time points. CKD-induced alterations to marrow perfusion 
were not corrected by PTH suppression, in contrast to CKD-induced elevation in 
cortical bone perfusion (Chapter 4). The lack of normalization of CKD-induced 
lowering of marrow perfusion in the low PTH/low remodeling CKD state suggests 
that marrow perfusion is not dependent on the high remodeling state in the 
setting of CKD. In addition to well-described mineral disturbances and hormonal 
factors that influence osteoclast differentiation in CKD, osteoclast differentiation 
and activity may be further exacerbated by decreased marrow perfusion resulting 
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in medullary hypoxia. Medullary hypoxia has been shown to induce osteoclast 
and inhibit osteoblast differentiation [81]. 
Reductions in marrow perfusion in the setting of CKD suggest either a 
dramatic shift in marrow VEGF signaling or marrow content during the later-stage 
manifestation of CKD. Previous work from our group has demonstrated lower 
levels of VEGF-A expression in bone marrow of 35-week old CKD animals 
compared to their normal littermates [107]. Concurrently, there is evidence of 
decreased marrow cellularity, increased marrow adiposity and increased marrow 
fibrosis [187]. Further investigation will require the determination of the 
relationship between these various factors. Do reductions in perfusion begin a 
cascade of marrow content alteration that results in lower levels of VEGF 
expression? Does VEGF expression occur first, resulting in reductions in marrow 
perfusion that then drives the changes in marrow content? Or are both reductions 
of VEGF expression and reductions in perfusion secondary to a change in 
marrow content that is occurring through another mechanism altogether? (see 
Table 6-2 sections 2a-b, 6a).   
A likely alternative explanation is that more severe vascular dysfunction 
with progressive renal failure may limit the ability to perfuse distal organs such as 
bone at late stage CKD [173]. Our work in Chapter 5 shows that in our CKD 
model, rats with progressive kidney disease have dysfunctions of vascular 
reactivity in large vessels, which could compromise end-organ perfusion 
including that of bone. In health, the main blood supply of the marrow originates 
from the nutrient artery, which originates from large arteries of the extremities (i.e 
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femoral/tibial and brachial/radial arteries), penetrates the cortex and divides into 
ascending and descending branching running along the length of the bone within 
the medullary cavity [128]. The main nutrient artery running longitudinally through 
the medullary cavity will supply the medullary sinuses in the marrow along with 
cortical branches directed back toward the endosteum. Any disturbances to the 
vascular supply to the nutrient artery (including decreased vascular reactivity of 
large arteries) will result in decreased perfusion to the marrow.   
The lack of normalization of CKD-induced lowering of marrow perfusion in the 
low PTH/low remodeling CKD state suggests that marrow perfusion is less 
dependent on the high remodeling state in the setting of CKD and more 
dependent on vascular dysfunction of CKD. Likely, the CKD-induced lowering of 
marrow perfusion observed in high PTH/high remodeling CKD is due to 
compromised blood supply (vascular delivery or vascular volume) or 
dysregulated signaling/pathology that affects the bone vascular network. 
 
Clinical Implications 
The clinical importance of the bone vascular system lies mainly in its 
ability/permissiveness to deliver 1) nutrients/oxygen, 2) cells with cancerous 
potential, and 3) therapies to bone and marrow tissue. The bone vascular system 
is paramount to the delivery of nutrients/oxygen to bone. The delivery of 
nutrients/oxygen to bone becomes clinically relevant, broadly, in two categories: 
altered vasculature that affects bone health and function, or altered bone 
metabolism requires an increased delivery of nutrients/oxygen to bone. The 
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delivery of cells with cancerous potential to bone is obviously of clinical 
importance. Bone is the third most common site of cancer metastasis after the 
lung and the liver, potentially due to marrow vascularity and permeability of 
marrow sinusoids [197]. The delivery of therapies to bone is dependent on the 
viability and activity of the bone vascular system. As the conduit of nutrients 
necessary for health and function, cells that have cancerous potential, and 
therapies that can fix or poison bone tissue, the bone vascular network is 
clinically important. In the following sections, the clinical implications of our 
findings will be discussed.  
 
Clinical implications of CKD-induced elevations in cortical bone perfusion 
Elevated perfusion to the cortical bone in chronic kidney disease results in 
relatively increased delivery of nutrients/oxygen, presumably, as detailed in 
above sections, in response to increased metabolic demand. Although delivery of 
nutrients/oxygen is increased in cortical bone in CKD, the supply may not be 
increased in proportion to the increased metabolic demand (see Future Studies 
section 2b for elaboration on the potential for mismatched supply and demand 
with regards to cortical bone perfusion).  
A major implication of increased cortical bone perfusion is increased 
delivery of systemic therapies. This discussion will focus mostly on bone-targeted 
therapy, however, increased delivery of all systemic therapies may also be of 
clinical importance given that CKD patients often have many comorbidities 
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requiring a variety of therapies and increased exposure of bone to drugs with 
various toxicities may have a detrimental effect on bone health and function.  
Increased bisphosphonate accumulation in CKD may occur due to 
increased cortical bone perfusion. Bisphosphonates are a class of antiresorptive 
drugs that are effective in decreasing fracture risk in situations of bone loss. 
Secondary hyperparathyroidism in the setting of CKD can result in dramatically 
increased osteoclast differentiation and activity. Bisphosphonates would be 
advantageous in counteracting this increased osteoclast activity, and thus work 
to reverse the bone loss of CKD.  Bisphosphonate use in CKD is approved as an 
acceptable method of treatment of high turnover renal osteodystrophy in early 
CKD stages, and contraindicated in later stage CKD (stages 3-5), according to 
recommendations by the Kidney Disease Improving Global Outcomes committee 
(KDIGO). In a study performed to characterize how alterations in kidney function 
affect the distribution and accumulation of zoledronate, our group found that 
animals with early stage CKD (about 50% of normal kidney function) accumulate 
significantly higher amounts of zoledronate [188]. Although the field has 
hypothesized increased accumulation of bisphosphonate due to decreased 
filtration of bisphosphonates (which are renally cleared), the present work 
presents another potential and convincing explanation. Bisphosphonates are 
transported to bone surfaces via bone nutrient arteries and the bone vascular 
system where they bind hydroxyapatite in the bone matrix. Although decreased 
filtration has been cited as the reason for increased skeletal accumulation of 
bisphosphonate in CKD, increased cortical perfusion is likely to also play a role.  
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Bisphosphonates can be effective in attenuating bone loss in early stages 
of CKD, however, the increased cortical bone perfusion has the potential to alter 
the amount of drug delivered to bone surfaces and increase skeletal 
accumulation of bisphosphonate. Although the physiologic implications of the 
skeletal accumulation of bisphosphonates are not clear, in vitro studies indicate 
its potential cytotoxic effects in high doses [192][193]. 
In light of the findings of the present work (increased cortical bone 
perfusion in the setting of CKD) and increased skeletal accumulation of 
zoledronate in CKD [188], further investigation is necessary to better understand 
the relationship of regional bone perfusion and skeletal accumulation of 
bisphosphonate (see Table 6-2 section 4).                                        
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                 
Clinical implications of CKD-induced lowering of marrow perfusion 
Decreased bone marrow perfusion in the setting of CKD may contribute to 
marrow dysfunction and alterations, including anemia, along the course of CKD. 
Marrow function and cellularity are dependent on an intact medullary vascular 
network. Decreased marrow cellularity is paired with decreased marrow function 
[199], both corresponding with decreased perfusion to the marrow [198]. 
Reductions of marrow perfusion in the setting of CKD are accompanied by, albeit 
with no evidence of causation, decreased marrow cellularity, increased marrow 
adiposity [187] and increased marrow fibrosis. Despite the overwhelming impact 
of anemia on CKD dialysis patients, along with the crucial nature of the bone 
vascular network in the health and function of bone marrow, marrow perfusion 
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has not been studied as a potential culprit for disease or target for therapy. The 
major challenge in the clinical relevance of marrow perfusion is the 
inability/challenge in modulating levels of marrow perfusion. However, with 
further investigation, marrow perfusion can be identified as a clinical target for 
anemia therapy in end-stage renal disease patients (see Table 6-2 sections 2a-
b, 6a).   
 
Clinical measurement of bone perfusion  
Measurement of bone perfusion can serve as a biomarker for bone turnover in 
CKD with the potential to guide treatment course. The ability to measure bone 
perfusion in a noninvasive and serial manner has the potential of providing novel 
information with clinical utility in the longitudinal tracking of diagnosis and 
treatment of bone pathologies (e.g. 18F-Fluoride positron emission tomography in 
fracture healing and osteoarthritis [195]). A parallel can be drawn here with a field 
more advanced in utilizing perfusion measurements to gather clinically relevant 
information – oncology. The assessment of tumor perfusion has been used in 
diagnosis (i.e. angiogenic progression of the lesion) along with treatment efficacy 
(i.e. estimating adequate drug delivery along with longitudinal tracking)[194] and 
ultimately led to the development of anti-angiogenic drugs that are currently in 
use today [200]. Similarly, the noninvasive and serial measurement of bone 
perfusion in CKD can serve as a biomarker of bone turnover, and thus be of 
clinical utility in diagnoses and treatment efficacy tracking of renal 
osteodystrophy. Currently, serum PTH and serum BSAP are used as biomarkers 
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for serial tracking of bone turnover in CKD patients, even though it is known that 
they are poor markers [189]. The alternative is an invasive iliac crest bone biopsy 
for histological measure of bone turnover, but is not ideal as a longitudinal 
measure. Bone perfusion measurement presents a potential solution as a 
noninvasive and serial assessment of bone activity. Further studies will need to 
be performed to establish the relationship between clinically measured bone 
perfusion with histologically measured bone turnover (See Table 6-2 sections 5a-
b).  
 
Future Studies 
The current series of studies answers several important question with 
regards to skeletal perfusion in the setting of CKD, however, these results also 
lead to several more questions. Table 6-2 summarizes some potential 
experiments based on the results of this work.  
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Table 6-2: Description of future studies 
EXPERIMENT  DESCRIPTION  
1 - Reproducing results of CKD-induced elevations in cortical bone perfusion 
a) Cortical bone 
perfusion elevation 
in CKD bone with 
intracortical 
remodeling   
Utilizing higher order animal models 
(rabbit/dog/pig) of CKD that have intracortical 
remodeling to confirm the results presented 
in current work 
b) Translatability to 
CKD patients  
Clinical study to assess bone perfusion in 
patients with known CKD bone disease  
2 - Understanding the relationship between altered bone perfusion and bone 
deterioration in CKD 
a) Temporal 
relationship of bone 
deterioration and 
altered perfusion  
Utilizing an animal model of CKD-MBD to 
establish the temporal relationship of 
increased bone perfusion, increased bone 
turnover, and increased cortical porosity via 
longitudinal measures (animals euthanized at 
different ages). This will also allow the 
assessment of the temporal relationship of 
reductions in marrow perfusion and changes 
in marrow content: 
• Do reductions in perfusion begin a 
cascade of marrow content alteration 
that results in lower levels of VEGF 
expression? Does VEGF expression 
occur first, resulting in reductions in 
marrow perfusion that then drives the 
changes in marrow content? Or are 
both reductions of VEGF expression 
and reductions in perfusion secondary 
to a change in marrow content that is 
occurring through another mechanism 
altogether? 
b) Functional 
measures of altered 
perfusion 
Utilizing an animal model of CKD-MBD to 
perform functional assessments (e.g. 
measures of hypoxia, metabolic activity, 
oxygen consumption etc.) of altered bone 
perfusion. This will allow the testing of these 
hypotheses: 
• Increased cortical perfusion is a 
compensatory mechanism for 
increased metabolic demand  
• Even in the presence of increased 
cortical perfusion, hypoxia still plays 
105 
an active role in cortical bone 
deterioration  
• Marrow dysfunction in CKD is paired 
with decreased marrow perfusion, 
decreased marrow oxygen 
consumption, and increased marrow 
hypoxia. 
3- Uncoupling hyperparathyroidism and bone remodeling as drivers of 
altered bone perfusion in CKD 
a) Uncoupling the 
effects PTH and 
bone turnover on 
altered perfusion  
Utilizing an animal model of CKD-MBD to 
uncouple the effects of secondary 
hyperparathyroidism and resulting elevated 
bone turnover on the increased cortical bone 
perfusion. To accomplish this, at least 4 
groups will be necessary: 
• Normal 
• CKD – high PTH/high turnover 
• CKD – low PTH/low turnover 
• CKD – high PTH/low turnover  
b) Uncoupling the 
effects of continuous 
PTH and CKD on 
altered perfusion  
Utilizing normal animals and PTH therapy to 
uncouple the effects of high serum PTH 
levels and CKD on the increased cortical 
bone perfusion observed in CKD. To 
accomplish this, at least 3 groups will be 
necessary: 
• Normal 
• Normal + continuous PTH 
• CKD – high PTH/high turnover 
4- Understanding the relationship between regional bone perfusion and 
bisphosphonate accumulation  
a) Regional bone 
perfusion, 
bisphosphonate 
accumulation, and 
regional bone 
turnover  
Utilizing normal animals and fluorescently-
tagged bisphosphonate agents to measure 
bone perfusion, bisphosphonate 
accumulation and regional bone turnover in 
the same skeletal region at various bone 
sites. This study would test the hypothesis 
that regional perfusion dictates 
bisphosphonate accumulation at a specific 
skeletal site, and that the areas of 
accumulation will also have turnover 
suppression (whereas regions without 
bisphosphonate accumulation will not have 
turnover suppression) 
b) Bone perfusion 
imaging to measure 
Clinical study utilizing PET imaging in 
bisphosphonate-treated individuals to better 
understand the effect of bisphosphonates on 
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efficacy of 
zoledronate 
bone perfusion and bone metabolic demand. 
This allows the investigation of the potential 
that some skeletal regions prone to fracture 
do not receive the anti-resorptive effect of 
bisphosphonates due to dysfunctional 
vascular network or other factors of drug 
distribution 
5 - Understanding the relationship between regional bone perfusion and 
bone turnover to utilize bone perfusion as a biomarker of bone turnover in 
the treatment of renal osteodystrophy in CKD 
a) Regional bone 
turnover and 
regional perfusion 
Utilizing an animal model of CKD-MBD to 
investigate the relationship between regional 
bone turnover and regional bone perfusion at 
multiple bone sites 
b) Bone turnover and 
bone perfusion 
imaging  
Clinical study with matched bone biopsies 
and bone perfusion imaging  
6 - Understanding the effect of altered marrow perfusion on marrow health 
a) Nutrient artery 
ligation and anemia 
Utilizing normal animals and ligation of the 
principal nutrient artery of the femur to study 
the effects of disrupted perfusion on marrow 
health, and anemia specifically. This will also 
allow the investigation of the relationship 
between marrow perfusion, marrow VEGF, 
and marrow content. 
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Conclusion 
Assessment of skeletal perfusion in an animal model of progressive CKD 
demonstrated elevations in cortical bone perfusion in the setting of high 
parathyroid hormone (PTH)/high remodeling CKD, in combination with lower 
marrow perfusion. The elevation of cortical bone perfusion occurs despite the 
well-established evidence of vascular dysfunction in CKD. These data uncover a 
novel player in CKD-induced bone alterations. Currently, the primary goal of 
CKD-MBD therapy is the suppression of elevated levels of PTH utilizing calcitriol 
(and its analogues) and calcimimetics. In the present series of studies, we show 
that PTH suppression, utilizing both calcium supplementation and calcimimetic 
therapy, normalizes CKD-induced elevations in cortical bone perfusion. These 
data demonstrate that the combination of bone remodeling suppression and 
serum PTH reduction normalizes cortical bone perfusion in the setting of CKD. 
While the relationship of altered bone perfusion and bone deterioration in CKD 
necessitates further work, these results indicate that determining the 
mechanisms of bone perfusion alterations and whether they are drivers, 
propagators, or consequences of skeletal deterioration in CKD could help 
untangle a key player in CKD-induced bone alterations. 
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